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Background: Pulmonary rehabilitation for patients with Chronic Obstructive 
Pulmonary Disease (COPD) traditionally incorporates exercise training. Since 
COPD is characterised by periods of exacerbation of their disease, at this 
time patients may be unable to complete any exercise due to breathlessness 
or peripheral muscle weakness. Neuromuscular Electrical Stimulation (NMES) 
has been shown to improve the fundamental properties of muscles; therefore 
it has been hypothesised that NMES of the quadriceps femoris muscles may 
be able to maintain physical capacity during an exacerbation of COPD. 
Methods: A randomised controlled trial was designed. A sample of 20 
participants of mean (SD) age 70.5 (9.3)yrs admitted to hospital with an acute 
exacerbation of COPD (mean (SD) Forced Expiratory Volume in 1 second 
(FEV1) 0.82 (0.39) (30.4% predicted) were recruited. The group were 
randomised into an experimental group who undertook NMES of the 
quadriceps for 30 minutes each day, and were also encouraged to mobilise 
until constrained by symptoms; or randomised into a control group who 
undertook NMES using a ‘sham’ technique as well as being encouraged to 
mobilise until constrained by symptoms. Patients participated in the study for 
4 weeks. Quadriceps strength, and exercise capacity measured by 
Incremental Shuttle Walk Test (ISWT) were taken at baseline, on discharge 
from hospital and at 4 week follow-up. Patients also completed health related 
quality of life questionnaires, and were asked to wear an activity monitor 
during their in-patient stay. 
Results: There were no significant differences between the baseline 
measurements. In the experimental group (n=8) over the 4 week trial period 
there was an overall increase in quadriceps strength of 9.1 (SD 15.5)Nm 
(95%CI –22.0 to 3.9). The control group (n=5) also demonstrated an increase 
in quadriceps strength 37.4Nm (SD 104.6) (95%CI  -203.9 to 129.0). However 
neither of these increases were significant p<0.05, there were no differences 
between groups. ISWT performance was also improved in the experimental 
group, at baseline the mean (SD) distance was 21.0 (n=8) (SD 37.8)m. On 
discharge from hospital the mean had increased to 61.0 (SD 49.0)m (mean 
increase 40m) (95%CI –81.2 to1.2). This increase was not significant 
(p=0.056 (df=9), results showed a strong trend towards statistical significance. 
During the period from discharge to 4 weeks there was a significant increase 
in ISWT performance p=0.026 (df=5). The ISWT in the control group also 
increased again this was not a significant increase, mean baseline ISWT was 
10.0 (n=5) (SD 20.0)m (95%CI –291.7 to 81.7), at discharge the mean 
distance was 115.0 (SD 109.1)m (mean increase of 105m n=5) and at 4 
weeks the mean distance was 100.0 (SD 93.0)m (a mean increase of 90m 
from baseline to 4 weeks) from baseline to 4 weeks p=0.106 (df=4) (CI –214.7 
to 30.7). There were no statistically significant improvements in health related 
quality of life, however there were clinically significant improvements (>0.5 
change in score) in the mastery domain of the Chronic Respiratory 
Questionnaire (CRQ-SR) following NMES.  
Conclusion: This study has demonstrated that NMES is feasible during an 
acute exacerbation of COPD to maintain physical capacity, although it is 




The National Institute for Clinical Excellence (NICE) (2004) define Chronic 
Obstructive Pulmonary Disease (COPD) as a condition characterised by 
airflow limitation, which is progressive and not fully reversible; it is an umbrella 
term for what was previously known as Chronic Bronchitis and Emphysema. 
MacNee (2005) reiterates that chronic airflow limitation results from an 
inflammatory response to gases within the lungs and inhaled particles, 
predominantly caused by smoking. 
 
Airflow limitation occurs as a result of airway and paranchymal damage 
resulting from inflammation due predominantly to tobacco smoking. COPD is 
characterised by symptoms such as chronic cough and increased sputum 
production; disability and impaired quality of life (NICE 2004). Ries et al 
(2007) suggest that morbidity from COPD is high because affected individuals 
remain undiagnosed until their disease is relatively advanced due to the 
insidious onset of symptoms. It is also well documented that COPD is a major 
cause of hospital admission, disability, morbidity, and high health care 
expenditure (Yohannes and Connolly 2004). 
 
The World Health Organisation’s (WHO) world health report lists COPD as the 
fifth most common cause of death worldwide (Celli et al 2005). In the United 
Kingdom (UK) it is reported that COPD accounts for over 90000 admissions to 
hospital per year, this number has risen over the past 10 years costing 
approximately £817.5m (Ram et al 2004). This translates to a prevalence of 
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66-69/1000 population (Sillen et al 2009). This illustrates the extent the socio-
economic burden has extending beyond the individual but also on society.  
 
Diagnosis                                                                                                                          
NICE (2004) recommend that a diagnosis should be considered if a patient is 
over the age of 35 and presents with a risk factor, (commonly smoking) who 
demonstrates breathlessness on exertion, chronic cough, sputum production 
and winter ‘bronchitis’ or wheeze. 
 
The severity of airflow limitation should then be determined by pulmonary 
function tests (spirometry). These tests aim to detect and define abnormal 
lung function, allow assessment of lung function and to monitor the effect of 
treatment and progression of the disease (Axford 1996). The test commonly 
measures both the volume of air expelled in the first second of forced 
expiration (FEV1), and the total volume that can be expelled in a single 
expiration (forced vital capacity FVC). The Global Initiative for Chronic 
Obstructive Pulmonary Disease (GOLD) (2006) define mild COPD as 
FEV1/FVC <70% FEV1≥80% predicted, moderate COPD as FEV1/FVC <70% 
50%≤ FEV1 80% predicted, severe COPD as FEV1/FVC <70%, 30%≤ FEV 1 
,50% predicted and very severe COPD as FEV1/FVC <70%, FEV1 <30% 
predicted or FEV1 <50% predicted plus chronic respiratory failure. 
 
Disease Monitoring 
Initial investigations into the progression of COPD incorporate pulmonary 
function tests. The FEV1 measurements are a highly predictive factor in the 
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clinical outcome of COPD exacerbations (Willaert et al 2002). Although 
spirometry has its uses in assessing lung function further research suggests 
that the assessment of COPD is more complicated and incorporates other 
factors. Celli et al (2005) concur by implying that since COPD has a complex 
pathophysiology factors other than FEV1 need to be considered. They 
proposed a model of evaluation called the BODE index. The four factors 
identified were Body Mass Index (B), airflow obstruction (O), dyspnoea (D), 
and exercise capacity (E). This index is able to correlate patients with their 
prognosis; the BODE index scoring is predictive not only for death from 
respiratory causes but also from any other cause; scoring by quartiles is also 
more predictive than scoring by spirometry alone (Celli et al 2005).  
 
This is a comprehensive model as it incorporates not only the pulmonary 
aspects of the condition but also the systemic effects. This is illustrated by 
Eisner et al (2007) who note that low Body Mass Index (BMI) is associated 
with higher mortality in COPD and functional limitation; however they also 
found that a higher fat mass had a negative effect on function.  
 
Exacerbation 
COPD is a disease punctuated by periods of exacerbation. NICE (2003) 
define an exacerbation as, 
         “A sustained worsening of the patients’ condition from their usual 
stable state, and is acute in onset.” (NICE 2003). 
Willaert et al (2002) expand on this definition by stating that an exacerbation 
is characterised by increased dyspnoea, increased cough frequency or 
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severity, an increase in sputum production or purulence and increased 
wheeze. 
 
Man et al (2004) illustrate the relevance of exacerbation by stating that over 
the past decade admissions to hospital for acute exacerbations of COPD 
have increased by 50% in the UK. Acute exacerbations account for more than 
10% of acute medical admissions, and that many deaths occur during 
admission or shortly following discharge. For the patient this is associated 
with impaired quality of life, and an increased likelihood of readmission 
(Hosker et al 2006). Garcia–Aymerich et al (2003) comment that patients with 
COPD suffer recurrent exacerbations with worsening symptoms and a further 
reduction in lung function, which is associated with high healthcare cost as a 
result of hospital admission. 
 
Risk factors for re-admission are clinical status, adherence to medication, 
lifestyle, quality of life and social support (Garcia-Aymerich et al 2003). 
Murphy et al (2005) also note that exacerbations of COPD are associated with 
a delay in lung function recovery of up to 12 weeks, during this period patients 
are susceptible to further exacerbation. Patients suffer a mean exacerbation 
rate of 2-4 per year (Seemungal et al 2000).   
 
It is therefore feasible to suggest that expenditure could be minimised if 
admissions to hospital were reduced. Yohannes and Connolly (2004) state 
that a patient with moderate to severe COPD is on average likely to suffer 
three exacerbations per year, with an average hospital stay of eleven days 
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per exacerbation. Pitta et al (2006) also note the negative impact 
exacerbation has on healthcare resources and survival, suggesting that this 
was linked in part to periods of inactivity. Following a retrospective audit, 
NICE (2003) reported that of 1400 patients admitted with exacerbation that 
34% were readmitted and 14% had died within 3 months.  
 
Hospital Admission and Muscle Force 
Repeated admission to hospital can have a profound detrimental effect on all 
aspects of the condition, and lead to a further decline in physical capacity and 
exercise tolerance. Peripheral muscle weakness is a known feature of COPD. 
An important piece of research which informs the current study was 
conducted by Spruit et al (2003) who demonstrated a decline in muscle 
strength in hospitalised patients suffering an exacerbation, compared with 
stable patients; it was suggested that peripheral muscle force declined 
throughout a hospital admission and was at its lowest at day 3. Possible 
causes were related to changes in nutritional, metabolic, oxidative and 
inflammatory responses at the time of exacerbation, in addition to bed rest. 
Peripheral muscle force declines in approximately 30% of all COPD patients 
(ATS/ERS 2006). 
  
The results of Spruit et al (2003) showed that on admission hospitalised 
patients had lower mean Quadriceps muscle Peak Torque (QPT) (66 (22)% 
predicted) compared to stable patients, and that QPT declined between days 
3-8 of admission, and that this may relate to the levels of circulating 
inflammatory markers Insulin-like growth factor Ι (IGF-Ι) and Interleukin 8 
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(CXCL8). Patients who have frequent exacerbations also have a faster 
decline in functional status than those with infrequent exacerbations, 
measured by quality of life questionnaires (Wedizcha and Wilkinson 2006).  
 
Pitta et al (2006) conducted another important study which concluded that 
patients who suffered ≥1 exacerbation per yea r for which they were 
hospitalised showed decreased walking distances 1 month following, and 
patients with the lowest distances were the most likely to be re-admitted to 
hospital. This paper and the paper by Spruit et al (2003) indicate a need for 
some therapy to be aimed at the peripheral muscle.      
 
Pulmonary Rehabilitation 
The American Thoracic Society/European Respiratory Society (ATS/ERS) 
(2006) define rehabilitation as a comprehensive intervention, which has 
demonstrated reductions in dyspnoea, increased exercise tolerance and an 
improved health related quality of life. NICE (2003) suggest that pulmonary 
rehabilitation is a process used for patients with COPD, and is designed to 
optimise the individual’s social and physical performance, and autonomy. The 
evidence in favour of rehabilitation is overwhelming in improving physical 
function and quality of life. 
 
Although the consensus is that pulmonary rehabilitation is of benefit, it is not 
always available to those who need it. Clini et al (2001) report that although it 
is widely recognised that rehabilitation is effective in enhancing standard 
therapy and alleviating symptoms, that programmes are costly and facilities 
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are limited therefore careful selection of patients is required. Yohannes and 
Connolly (2004) comment that in the UK only a third of acute hospitals provide 
pulmonary rehabilitation. 
 
Exercise training is at the cornerstone of pulmonary rehabilitation (Spruit 
2004). Reardon et al (2005) concur by suggesting that since peripheral 
muscle dysfunction is a major cause of reduced function in COPD patients 
that physical training is vital to increase exercise capacity, functional status 
and quality of life. 
 
Rehabilitation is important in the management of COPD, and exercise is a 
vital component of this. However for those suffering an exacerbation of their 
condition completing a traditional course of rehabilitation may be difficult as 
they are constrained by their symptoms. The aim of this study is to propose a 
novel way of maintaining physical capacity during an exacerbation, 
commencing while the patient is hospitalised; which as previously discussed 
is when physical capacity could be further diminished.  
 
Puhan et al (2005) found that following successful rehabilitation immediately 
after exacerbation the mean numbers of readmissions to hospital were 
reduced from 1.6-0.9 in the following year. Previous research suggests that 
following exacerbation the recovery period is long. Puhan et al (2005) note 
that if rehabilitation is commenced during this period that it can improve 
prognosis and quality of life. Patients undergoing early rehabilitation were 
readmitted 30% less often than those in the control group, and there was a 
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This study is a rehabilitation based intervention commenced during the acute 
phase of the disease. Therefore this section will examine how to identify the 
impact of COPD on the individual, types of training that are commonly 
employed, the value of exercise training during an exacerbation of the 
disease; and the previous literature surrounding the rehabilitative strategies 
discussed.  
 
ATS/ERS (2006) suggest that pulmonary rehabilitation programmes 
traditionally include patient assessment, exercise training, education, 
nutritional intervention and psychosocial support. Prior to rehabilitation it is 
imperative to undertake a thorough assessment of the patient’s condition to 
tailor the rehabilitation to meet the needs of the individual. Reardon et al 
(2005) state that coordinated action is required by a multidisciplinary team in 
order to deliver individualised rehabilitation.  
 
Assessment of Patients with COPD 
Walking Performance 
Cress et al (1996) state that physical performance tests have become popular 
due to concerns that self-reported function may provide insufficient 
information about disability. Schonhofer et al (1997) illustrate the validity of 
walking tests by stating that tests based on walking speed are widely used 
and consistently correlate with self-reported exercise limitation. Exercise 
testing in COPD varies from simple field tests to maximal laboratory tests that 
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necessitate the use of technical equipment (Arnardottir et al 2006).  
 
To avoid the use of technical equipment field tests such as the 6-minute 
walking distance (6MWD) and the Incremental Shuttle Walk Test (ISWT) are 
employed. Behnke et al (2005) state that the 6MWD and the 6-minute 
treadmill walking distance have been introduced as measures of exercise 
capacity, and have shown a correlation between these measures and the 
activities of daily living. The ATS (2002) note that in the 1960’s Balke 
formulated a simple test to assess functional capacity by measuring the 
distance walking during a specified time, and that this was a simple and 
practical test. The 6MWD demonstrates the most variability in its application, 
and that although these tests are useful objective measures for programmes it 
is unclear how they translate into activities of daily living (ATS/ERS 2006). 
The 6MWD may be more suitable for those with severe COPD due to its self-
paced protocol (Turner et al 2004). 
 
An alternative is the ISWT developed by Singh et al (1992) they described a 
walking test over a 10-metre course incorporating audio signals to control 
pace. Singh et al (1994) note that a benefit of this test is that it is externally 
paced and therefore influenced less by encouragement. Because it is 
incremental it stresses the patient to a symptom-limited performance. This is 
of benefit when assessing the outcomes of rehabilitation as it can be used to 
compare pre and post training responses at an equivalent level of intensity of 
exercise (Turner et al 2004). This was followed by the development of the 
Endurance Shuttle Walk Test (ESWT) formulated by Revill et al (1999) this 
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was designed to complement the ISWT in order to standardise walking speed 
and allow endurance exercise capacity to be assessed. 
 
To summarise, the protocols are very different, the 6MWD is self paced and 
can be continuous or intermittent. The ISWT is externally paced and is 
conducted over a 10 metre course, and requires an increase in walking speed 
until the test is halted due to breathlessness or fatigue; or if the patient fails to 
reach the cone in the time allowed (Turner et al 2004).  
 
Brcukink et al (1998) found that patients with chronic conditions such as 
COPD reported an increase in the perception of fatigue when in a clinical 
setting and that there is a relationship between subjective fatigue, pulmonary 
function and peripheral muscle force. A reason for this fatigue at peripheral 
muscle level is cited by Richardson et al (2004) who suggest that COPD 
patients display an increase in the proportion of type ΙΙ muscle fibres, either 
assessed histochemically or by the expression of myosin heavy chains, the 
opposite in fibre changes is demonstrated in healthy ageing; the authors 
hypothesise that this change in fibre composition could be related to exposure 
to periods of reduced oxygen availability, or muscle disuse both of which 
occur in COPD.   
 
It has been proposed that peripheral muscle weakness contributes to exercise 
intolerance. Bernard et al (1998) state that peripheral muscle weakness is 
commonly observed in patients with COPD and recently possible links to 
exercise intolerance have been recognised. Jones et al (2004) cited by 
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Reardon et al (2005) further suggest that muscle deconditioning occurs 
quickly as a consequence of muscle inactivity, this is because muscle mass 
and the expression of genes associated with muscle growth are reduced with 
muscle immobilisation.  
 
Exercise tolerance can also decline due to a decrease in cardiovascular 
function secondary to inactivity. ATS/ERS (2006) illustrate this by stating that 
inactivity can lead to cardiovascular deconditioning, this deconditioning could 
also be exaggerated during a hospital admission. These factors could 
possibly be managed with the incorporation of pulmonary rehabilitation.  
 
Breathlessness 
Exertional dyspnoea is perhaps the commonest complaint of patients with 
COPD. Dyspnoea can be assessed in various circumstances, for example 
breathlessness during exercise exertion and breathlessness during the 
activities of daily living (Oga et al 2005). Patients with COPD often find it 
difficult to complete their activities of daily living. It is feasible to suggest that 
patients may be even more exhausted when undertaking exercise as part of a 
rehabilitation programme, particularly during an exacerbation.  
 
The measurement of dyspnoea is important; its severity and impact on a 
person’s functioning can be evaluated (Eakin et al 1998). Measurements of 
breathlessness can be taken using several different methods. Ozalevli et al 
(2006) state that one such method is the Modified Borg Scale (MBS) this is a 
modified form of the original Borg scale (Borg 1982) which rates perceived 
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exertion to measure symptoms such as breathlessness on a non-linear 10-
point scale (appendix 1). They did however find that although this is a widely 
used scale that in their study there was, as anticipated no relationship 
between MBS and pulmonary function, and that the Medical Research 
Council (MRC) (appendix 2) scale appeared to be more compatible for noting 
change in FEV1 values as they are both measured at rest. Therefore for this 
study both will be utilised. The MRC can also be used to assess how 
breathless a patient is at rest. Bestell et al (1999) confirm that the MRC 
dyspnoea scale has been used for many years to grade the effect of 
breathlessness on daily activities. Patients who demonstrate breathlessness 
during daily activities score an MRC 3 or above up to 5. The MRC is also of 
relevance as it correlates with the ISWT (Bestall et al (1999).  
 
Quadriceps Strength 
Garcia-Aymerich et al (2006) recommend that COPD patients should aim to 
maintain or increase levels of regular physical activity in order to reduce the 
risk of admission to hospital. A seminal paper by Pitta et al (2006) iterates that 
during hospitalisation patients had a very low level of physical activity and 
spent very little time in weight bearing activities. They reported that by day 8 
of an admission quadriceps strength was significantly reduced. Spruit (2004) 
suggests that a reduction in a patient’s functional capacity is closely related to 
quadriceps muscle weakness. Swallow et al (2007) also found that 
quadriceps muscle strength can add prognostic information to identify high-
risk patients who may benefit from rehabilitation. Coronell et al (2004) 
illustrate the relevance of assessing quadriceps strength by stating that even 
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those with clinically stable COPD display impairment of the quadriceps.    
 
Studies have indicated that quadriceps strength and cross-sectional area are 
associated with the degree of airflow limitation, a positive relationship was 
found between predicted FEV1 percentages and quadriceps strength (r=0.55, 
p<0.0001) suggesting that there is a correlation between a decrease in FEV1 
translating to a decrease in quadriceps strength (Bernard et al 1998). Bernard 
et al (1998) also note that malnutrition and hypoxia can contribute to muscle 
weakness, and although a patient may present with a normal BMI this does 
not exclude malnutrition as a factor in muscle weakness because muscle 
mass is lost faster than body weight. Therefore although body mass is a 
prognostic factor in COPD, studies show that mid-thigh cross sectional area is 
more closely related to survival than body weight (Marquis et al 2002). 
O’Shea et al (2004) suggest that quadriceps muscle cross-sectional area can 
be increased by up to 8% following strength training.  
 
These findings suggest that the quadriceps would be a valid muscle to focus 
on when implementing involuntary muscle training in rehabilitation during an 
acute exacerbation. The quadriceps femoris is an important muscle to 
concentrate on in rehabilitation programmes as identified above. One further 
reason for this is illustrated by Salman et al (2003) who conducted a meta-
analysis surrounding respiratory muscle training. They concluded that 
research into exercising respiratory muscles alone demonstrated no 
significant improvements in exercise tolerance between the experimental and 
control groups. Whereas trials that incorporated lower extremity training 
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showed that the experimental rehabilitation groups did significantly better in 
dyspnoea and walking tests. There is also a relationship between muscle 
weakness and the use of steroids (Decramer et al 1997). This provides 
another contributing factor for a decline in quadriceps strength.  
 
It could be hypothesised that during an admission for exacerbation that 
physical activity will be reduced contributing to further quadriceps muscle 
weakness. Spruit et al (2003) found that muscle force was significantly 
reduced during a hospital admission, they noted that between days 3-8 
quadriceps peak torque decreased 5% of predicted (95% CI –22 to 8, 
p=0.05).  Pitta et al (2006) concur by suggesting that following an 8-day 
admission to hospital for exacerbation that there was a significant reduction in 
quadriceps strength (median –5% of the predicted value) ([IQR –1 to –12%] 
p=0.04). 
 
 However the authors note that the decline in quadriceps strength may be 
caused by underlying factors which attribute to inactivity; the authors also 
noted just how strikingly inactive patients are during hospitalisation by day 2 
patients only spent a median of 7% of time in weight bearing activities by 
discharge this had only increased to 9%. They noted that during admission 
muscle force decreased by 7% predicted, when you consider that following 6 
months of rehabilitation muscle force only increases by 20%, a loss of 7% in 5 
days seems very relevant. Tudor-Locke et al (2008) note that previous studies 




This implies that in hospital there is pronounced inactivity that is a significant 
contributing factor in the decline of muscle force. The findings of these 
seminal papers illustrate the importance of intervening early on in an 
exacerbation and while patients are hospitalised in a bid to halt further decline 
in muscle force and physical function. 
 
There are several different methods which can be adopted to ascertain 
quadriceps strength. The most common method used is Isometric Maximum 
Voluntary Contraction using isokinetic dynamometry, there are also handheld 
dynamometers which do not require taking the patient out of the ward area to 
use the equipment. A study by Martin et al (2006) noted that the handheld 
method was valid for quick and objective measurement of quadriceps strength 
in the clinical setting. However the handheld method relies on the user having 
enough strength to resist the muscle force that the subject is able to generate.  
Other more sophisticated methods of measuring the quadriceps cross 
sectional area include Computerised Tomography (CT) and Magnetic 
Resonance Imaging (MRI) scanning; ultrasound is an alternative less costly 
method which can be used at the bedside. Femoral nerve stimulation can also 
be incorporated, although it is the gold standard it is not widely available and 
is expensive (Seymour et al 2009). Chair fixed dynamometers can also be 
used. Gagnon et al (2005) conducted a study which aimed to validate the 
chair fixed dynamometer as a strain gauge measure; they concluded that high 
indices of inter-trial and inter-rater reliability were found validating its use in 
the clinical setting; however the chair fixed dynamometer and isokinetric 
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dynamometry should not be used interchangeably.   
 
Activities of Daily Living and Quality of Life 
A broad assessment of daily activity can be gained from the use of 
questionnaires. Puhan et al (2005) state that clinicians recognise the 
importance of measuring health-related quality of life as an important outcome 
measure in clinical trials for those suffering with COPD and other respiratory 
illnesses. Although current guidelines define the severity of COPD in terms of 
FEV1 measurements, other health status measurements may well 
complement FEV1 results when characterising the impact of a person’s 
disease (Bestall et al 1999).  
 
Health Status 
As previously outlined NICE (2007) state that the MRC dyspnoea scale can 
be used to grade the patient’s perceived breathlessness on daily activities in 
the patients usual state. Bestall et al (1999) suggest that this is a simple valid 
method of categorising COPD patients with their disability. The Chronic 
Respiratory Questionnaire (CRQ) (appendix 3) is another commonly used 
assessment tool. This tool has 20 questions about the level of disability in the 
domains of dyspnoea, fatigue, emotional function and mastery (Guyatt et al 
1987). Patients score their level of impairment on a scale of 1-7 in each 
portion of the questionnaire. The authors found that because the CRQ is 
disease specific it is more responsive when compared to generic tools when 
evaluating pulmonary rehabilitation. Williams et al (2001) found that when the 
CRQ was self-reported as opposed to interviewer led it gave patients a 
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greater sense of privacy, and that results were comparable to the gold 
standard interviewer led version.  
 
Anxiety and Depression 
The Hospital Anxiety and Depression scale (HADS) (appendix 4) assesses 
emotional state (Zigmund and Snaith 1983). This questionnaire comprises of 
14 items, which separately assess anxiety and depression. They score up to 
21 and a score of over 10 indicates significant levels of anxiety or depression. 
Studies have found that depression in COPD can be related to functional 




Previously activities of daily living were estimated by the use of questionnaires 
or diary keeping, however self-reporting can often be inaccurate. Pitta et al 
(2005) advocated the use of activity monitors over questionnaires, suggesting 
that 69% of respondents overestimated their walking time. If self-reporting 
was a sole measurement in a piece of research this could lead to highly 
erroneous results of time spent walking and distance travelled. Daily activity 
can be measured using an activity monitor. Schonhofer et al (1997) reported 
that repeatable measures of daily activity could be gained from simple 
pedometers, however more useful were monitors which not only recorded 
numbers of steps taken but also vertical motion not just motion of the legs.  
 
There are some concerns over the responsiveness of the motion sensors, for 
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example there are some activities in daily life and in exercise programmes 
that do not include total body movement, possibly isolated upper body 
movement (Pitta et al 2005). Therefore any monitor used needs to be 
sensitive enough to detect these activities, a multiaxial device may offer a 
solution. Once calibrated to walking speed, activity monitors can differentiate 
between normal walking speeds and those prescribed as part of rehabilitation 
(Hunter et al 2006).  
 
Singh and Morgan (2001) further advocate the use of activity monitors by 
suggesting that they have the ability to differentiate between brisk walking and 
low-level domestic activities. The importance of a moderate level of daily 
activity was iterated by Garcia-Aymerich et al (2003) who note that patients 
with COPD who have a high level of daily activity are at a reduced risk of 
readmission due to exacerbation, the third of patients who reported 
undertaking ≥60minutes a day of an activity equivalent to walking, displayed a 
reduction in the risk of readmission to hospital of up to 50%. Garcia-Aymerich 
et al (2006) reiterated their findings by stating that a follow up study of 2386 
patients over a 20 year period found that a level of physical activity equivalent 
to walking or cycling for up to 2 hours a week was associated with a reduction 
in hospital admission of 30-40%. Their results noted that subjects reporting a 
low, medium or high level of physical activity had a lower risk of re-admission 
to hospital compared to those who reported a very low level of physical 




Exercise training  
Exercise is a vital component of pulmonary rehabilitation. The ATS/ERS 
(2006) indicate exercise training for those with decreased exercise tolerance, 
exertional dyspnoea, fatigue and impairment of activities of daily living in 
stable COPD. There is however controversy over the optimal training regime 
to adopt. Bernard et al (1999) state that although exercise training is an 




Spruit et al (2002) define strength (resistance) training as a mode of exercise 
in which small groups of muscles are trained by the lifting of weights. Training 
sessions generally comprise of 2-4 sets of 6-12 repetitions at intensities 
ranging from 50-85% of one repetition maximum (ATS/ERS 2006). Spruit and 
Wouters (2007) reported that resistance training improves skeletal muscle 
force, and identified that a major advantage of this training is that is places 
less strain on the respiratory system. Resistance training can also be used for 
selective muscle training by the repetitive lifting of weights; this can be 
individually adapted to the needs of the patient (Spruit et al 2002).  
 
O’Shea et al (2004) state that strength training alone; based on 6-12 
repetitions of each exercise at an intensity ranging from 50-85% of one 
repetition maximum, is unlikely to cause change in aerobic capacity, and that 
more research would be needed to detect changes, if any in the 
cardiovascular fitness of patients. Mador et al (2004) reiterate this by reporting 
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that while strength training made muscles stronger this did not translate into 
improvements in exercise capacity. 
 
Endurance Training 
ATS/ERS (2006) state that walking and cycling are the most commonly 
applied modalities in endurance training. Endurance training commonly uses 
cycle ergometry, treadmill walking and arm cranking to achieve a peak 
workload, often based on perceived levels of dyspnoea or fatigue (Spruit et al 
2002). Sala et al (1999) state that endurance training including lower limb 
exercises have been consistently shown to relieve dyspnoea, and improve 
health related quality of life. Maltais et al (1996) hypothesised that a controlled 
endurance training programme could partially correct early rises in blood 
lactate levels and low concentrations of skeletal muscle oxidative enzymes in 
patients. Sala et al (1999) concur by reporting that improvements after 
endurance training were related to enhanced skeletal muscle bioenergetics 
rather than changes in ventilation. Their results showed that oxygen 
consumption (VO2) increased by 10-15% in the COPD patients and the 
control group (13-20%). 
 
Morgan (2005) states that most training centres on endurance training, which 
will improve exercise performance but will not affect the strength or mass of 
muscles. Spruit et al (2002) advocate resistance training as an alternative for 
patients who have difficulty in completing a high intensity endurance 
programme; although high intensity endurance training has been associated 
with significant improvements in peripheral muscle strength, dyspnoea and 
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quality of life. 
 
Combined Training 
 It is most likely that a combination of approaches would be optimal, 
incorporating strength and endurance training. Ortega et al (2002) reiterate 
this by suggesting that in their study the combined training group acquired 
most of the benefits of intervention, and that would provide an optimum 
strategy. They found that after 12 weeks of training that the duration of 
exercise was significantly higher in the combined group, than in the group 
who undertook strength training only (48.9±29 minutes) (p<0.01) versus 
(43.6±21 minutes). 
 
Bernard et al (1999) also found that combining strength with aerobic training 
is associated with significant increases in muscle strength (20±12% versus 
8±10% [mean±SD]) in the aerobic only group; and muscle mass increases of 
the quadriceps and pectoris major 8±13% and 15±9% respectively (p<0.001). 
There was an increase in latissimus dorsi muscle after training of a similar 
magnitude in both groups. These findings did not provide significant 
improvements in exercise capacity or quality of life.  
 
Interval Training 
Interval training constitutes periods of high intensity exercise followed by short 
periods of rest. Spruit and Wouters (2007) state that 20-40% of patients do 
not complete conventional rehabilitation programmes therefore it is 
reasonable to speculate that regular programmes do not meet the needs of all 
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patients. Vogiatzis et al (2002) advocate the use of interval training by 
reporting that it allows maximum exercise to be taken with a relatively low 
perception of dyspnoea, as breaks are taken regularly. Kamahara et al (2004) 
elucidate by noting that since it is difficult for patients to carry out exercise for 
long periods due to shortness of breath, interval training has been found to be 
more beneficial. For patients suffering an exacerbation of their disease, 
initially any form of physical exercise may prove too strenuous and cause 
patients to become dyspnoeaic.  
 
Involuntary Training 
General exercise training is of course voluntary; however during an 
exacerbation patients may feel too constrained by their symptoms to 
participate in such training, therefore rehabilitation incorporating involuntary 
training may be of benefit at this time. One such method is Neuromuscular 
Electrical Stimulation (NMES). Bax et al (2005) state that applying an 
electrical current to neuromuscular tissue triggers muscular contraction and 
that its objective is to improve fundamental muscle properties, intramuscular 
blood flow, maximum force output, and force endurance through repeated 
repetitions. Bourjeily-Habr et al (2002) iterate that stimulation can increase 
muscle capillary/fibre ratio, fibre cross-sectional area and the number of 
fibres. Holcomb (2005) concurs that electrically induced muscle contractions 
involve a selective recruitment of type ΙΙ muscle fibres; because type ΙΙ fibres 




Ward and Shkuratova (2002) state that NMES preferentially recruits fast 
twitch fast fatigue motor neurons. Muscle force is generated by two means, 
firstly central nervous system adaptation and fibre recruitment; and secondly 
by building muscle bulk. NMES can take place directly over the target muscle 
or indirectly by placing pads over the nerve trunk.   
 
This involuntary training could be particularly useful for COPD patients 
because it would optimise muscle properties without causing stress through 
worsening dyspnoea. NMES can improve lower limb ambulation, strength and 
endurance for those with incapacitating dyspnoea (Neder et al 2002). 
Holcomb (2005) concluded that NMES is not an adequate substitute for 
traditional resistance training, however these conclusions were reached by 
studying athletes not COPD patients for whom completion of traditional 
resistance training may not be feasible.  Spruit and Wouters (2007) suggest 
that for those patients with prolonged respiratory failure, that NMES can be 
used to improve skeletal muscle strength and maintain muscle mass during 
periods of immobilisation. Ip et al (2004) concur by stating that the exercise 
component of rehabilitation for frail patients should be low-impact and it is 
beneficial if the in-patient stay is short so that patients can return home. It is 
feasible that NMES could potentially minimise the period of admission, if 






 NMES has already been widely used to rehabilitate chronic conditions such 
as Chronic Heart Failure (CHF). Nurh et al (2003) investigated whether low 
frequency electrical stimulation (15Hz) of the quadriceps femoris could 
counteract detrimental changes in skeletal muscle. Their findings suggested 
that stimulation was beneficial as a treatment for improving physical condition 
and exercise tolerance. Dobsak et al (2006) demonstrated that stimulation 
could effectively counterbalance decreased physical capacity by increasing 
oxidative enzyme activity in skeletal muscle fibres. Harris et al (2003) note 
that in Chronic Heart Failure rehabilitation intervention may have benefits in 
reducing admission rates and mortality. Nurh et al (2003) suggest that data 
concerning the effects of muscle stimulation on patients with chronic 
conditions was scarce. At present there are only a few published studies 
incorporating NMES into COPD rehabilitation. 
 
Bourjeily-Habr et al (2002) hypothesised that electrical stimulation of the lower 
extremities could improve muscle strength and exercise tolerance in patients 
with moderate to severe COPD. Their study took a sample of eighteen 
patients who were recruited if they had a FEV1 of <65% of predicted value, 
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were below 70 years, and had self reported exercise limitation; and were 
otherwise medically stable. Patients were excluded from the trial if they had 
cardiovascular and neuromuscular disease, joint disease, previous pulmonary 
rehabilitation; or had recently suffered an exacerbation. 
 
Patients were randomised into a control and experimental group. Electrical 
stimulation was performed for 20 minutes a day on each limb for a 6-week 
period. The protocol adopted provided impulses of 50Hz lasting 200ms every 
1500ms, in an asymmetrical square wave pulse. Intensities were set to create 
a visible contraction ranging from 55mA to 120mA. The intensities were 
increased by 5mA each week.  The control group used the same setup but 
received no active stimulation.  
 
The findings of Bourjeily-Habr et al (2002) suggested that stimulation 
improved muscle strength and exercise capacity, quadriceps strength was 
improved significantly for the treatment group from 44.7 (6.5) to 55.2 (6.6) Nm 
units p=0.004; an increase in the ISWT illustrated a mean improvement of 
36.1% for the treatment group compared with 1.6% in the sham group 
(p=0.007). The conclusions of the study show that NMES may be used as a 
rehabilitative strategy however further research may be needed, as 18 is a 
small sample size. Further studies are needed to examine the long-term 
effects of stimulation and the mechanisms by which it works (Bourjeily-Habr et 
al 2002). However Bourjeily-Habr et al (2002) do note that stimulation does 
improve muscle strength and exercise capacity in COPD and could be a 
useful component in rehabilitation. 
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 Neder et al (2002) also explored NMES in stable COPD, again only using a 
small sample of 15 patients and used a training protocol, which centred 
around a symmetric biphasic square pulsed current at 50Hz (unlike the 
Bourjeily-Habr et al (2002) paper which used an asymmetrical waveform). In 
the first week the cycle was 15 minutes on each leg with 2 seconds on and 18 
seconds off. The second week it was applied to the leg for 30 minutes 5 
seconds on and 25 seconds off, then 10 seconds on and 30 seconds off 
thereafter. Patients were asked to continue up to the highest tolerable 
amplitude. This was conducted on an out-patient basis. 
 
The findings of Neder et al (2002) concurred with those of Bourjeily-Habr et al 
(2002) that after a 6-week period, stimulation improved some markers of 
skeletal muscle strength and endurance of COPD patients, there were 
significant differences in maximal isokinetic strength (using an isokinetic 
dynamometer), difference between mean isometric force 21.2 (-10.8 to 53.2) 
Newtons (N); and muscle fatigue index % (difference between means –23.2 (-
42.5 to –3.9) were found between the two groups in favour of NMES, however 
indices of muscle endurance such as mean power and total work did identify 
trends towards improvements however not to a significant level. NMES did 
result in significant improvements in whole body incremental and exercise 
peak oxygen uptake (VO2) during endurance following NMES mean VO2 
increased by 0.13% (95%CI 0.03-0.23) p<0.05, this was significantly higher 
than the group undertaking a control period, and despite the differences in 
training protocol. Again, the authors also recognised that they were limited by 
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the small sample size. 
 
More recently research carried out by Vivodtzev et al (2006) recruited a 
sample of 17 in-patients who had recently suffered exacerbation, or had been 
admitted to an intensive care unit (FEV1 30±3%). Their study took place over 
one month all patients were randomly assigned to usual rehabilitation or 
rehabilitation plus NMES. Vivodtzev et al (2006) concluded that NMES did 
improve quadriceps strength and dyspnoea when performing daily activities; 
however this increase in quadriceps strength did not correlate with better 
results in the 6 minute walking distance. They noted that changes in muscle 
strength were correlated to changes in muscle mass (r=0.94; p=0.03 
[spearman correlation]). Although there was an increase in 6MWD (63±40m; 
p=0.01) in the treatment group, the between group difference was not 
significant (p=0.12). This is possibly due to the fact that the patients recruited 
for the study were more severely deconditioned and malnourished, whereas 
in the previous studies subjects were stable, therefore their improvements 
were bigger.  
 
Following treatment Maximal Volitional Contraction (MVC) of the quadriceps 
using an isokinetic dynamometer significantly increased in both groups. The 
group which did NMES plus traditional rehabilitation demonstrated an 
increase in MVC (97±71 contractions; increase 35%). Vivodtzev et al (2006) 
reported that MVC was increased by (36±35 contractions increase 14% 
p=0.03) in the group which completed traditional rehabilitation only. Therefore 
although increases were significant for both groups there was a two-fold 
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improvement in the NMES group. 
 
A study conducted by Zanotti et al (2003) recruited 24 in-patients from an 
intensive care unit suffering from respiratory failure due to COPD and applied 
square wave symmetric impulses from 8-35Hz for up to 30 minutes per day 
for 28 days. They found that subjects had improved peripheral muscle 
strength (2.16±1.02 vs 1.25±0.75, p=0.02) (muscle strength scored from 0-5), 
which resulted in being able to sit out of bed earlier, and consequently that 
their duration in intensive care was shortened. The NMES group were 
transferred from bed to chair 10.75 ± 2.41 days versus 14.33 ± 2.53 days for 
the control group.  Again this study advocates the use of NMES, and although 
the sample were all mechanically ventilated they were medically stable and 
excluded if suffering from an exacerbation of their COPD. Therefore they were 
most likely to be long term patients weaning from the ventilators due to poor 
lung compliance. It is difficult to make direct comparisons between the 
improvements in muscle function in this study and the previous noted 
because an arbitrary scoring system was used opposed to objective 
measurement.  The patients chosen for this study represented the closest 
available to a true control group as all of the patients had been confined to 
bed. 
 
A recent crossover study conducted by Dal Corso et al (2007) found that 
following 6 weeks of NMES at a frequency of 50Hz NMES caused a 
significant increase in type ΙΙ muscle fibres, and a decrease in type Ι cross 
sectional area (median change range)=12.5% (-16.8% to 57.6%) vs -9.8% (-
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40.8 to 36.6%) (p<0.05). This did not correlate with significant improvements 
in isokinetic quadriceps strength or the 6MWD. Following NMES peak torque 
was 103.2±50.6Nm and 6MWD 502±68m, for the sham group peak torque 
was 101.8±37.7Nm and for the 6MWD 500±56m there was no significant 
increase p>0.05 for either group. 6MWD results were high this could be 
related to the patients studied who were all stable outpatients demonstrating 
an MRC II-III score. Dal Corso et al (2007) reiterate that a reason for the 
discrepancies in results between their study and previous ones is that this 
study evaluated patients who were not severely impaired. It is likely that 
NMES is more effective for those possibly recovering from an exacerbation of 
COPD; however this hypothesis would need adequately testing (Dal Corso et 
al 2007). 
 
These studies are all limited by their small sample sizes, and the authors 
suggest that larger trials are required to validate the findings of preliminary 
trials and elucidate on the most effective protocol. A review by Sillen et al 
(2009) implies that improvements following NMES appear to be clinically 
relevant, the mean increase in ISWT distance between sham and therapeutic 
stimulation in the studies they reviewed was 68.8metres; above the 47metres 
required to mark a clinically significant improvement.  
 
It would appear that all of the studies reported excluded patients suffering 
exacerbation. Zanotti et al (2003) state that NMES is safe and reliable and 
can be performed in any hospital setting; therefore it is feasible to suggest 
that it could be performed on patients admitted with an exacerbation of their 
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disease. Intervention at this time could improve muscle strength without 
causing dyspnoea as illustrated by previous research. Neder et al (2002) 
elucidate this by stating that during the trial period four patients suffered a 
mild exacerbation but were able to continue with the protocol without any 
adverse events. A review by Roig and Reid (2009) noted that at present 
NMES has the potential to be used as an adjuvant therapy to rehabilitation, 
that it may only be beneficial as a primary intervention during the acute phase 
of illness when a patient is confined to bed. 
 
There is not however any consensus about the best protocol of NMES to be 
used. An example of this is that the study by Vivodtzev et al (2006) which 
incorporated a longer duty cycle (contraction/relaxation time) than that of the 
other studies, does this have any discernible effect on the outcome measures 
of the study?  
 
Application/ protocol 
Ward and Shkuratova (2002) reported that early work carried out in Russia 
advocated use of the 10:50:10 protocol for NMES, where stimulation would be 
applied for 10 seconds followed by 50 seconds rest for 10 minutes. However 
although this is still widely used there is little published evidence to support 
this protocol. After evaluating previous work, Ward and Shkuratova (2002) 
conclude that there needs to more comparison studies into whether this ‘on’ 
‘off’ regime is the most effective. Despite this it is variations on this regime 
which are most widely used in the reported studies. 
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Laufer et al (2001) conducted a study comparing three different waveforms; 
monophasic, biphasic, and polyphasic waveforms. The first two generated by 
a battery-powered stimulator that could be used in a patient’s home, and the 
polyphasic waveforms generated by alternating current driven stimulators 
used in clinics. They reported previous research shows that for recovery of 
quadriceps strength, higher intensity clinical stimulators were recommended. 
This is important because research into portable stimulators could decrease 
expenditure, and could be used at home. The authors found that results from 
battery-powered stimulators illustrated that waveforms were comparable to 
those generated by those used in clinics. It is also worth noting that Laufer et 
al (2001) were investigating quadriceps strength of volunteers with a mean 
age of 28.2 years with no muscular or skeletal impairment. It is possible that 
for COPD patients with peripheral muscle weakness that lower intensities may 
be effective as previously illustrated. 
 
Differences between portable and clinical stimulators have also been reported 
by Lyons et al (2005). Their study used the Empi-300PV™, which is used for 
this study. This is a multifunction electrotherapy device capable of providing 
NMES to activate specific muscles. Lyons et al (2005) reiterated the findings 
of Laufer et al (2001) by stating that both stimulators produced comparable 
levels of quadriceps muscle torque (using a computerised dynamometer) 
when the subject’s maximum tolerance was used as the criteria for the 
selection of stimulus, this means that the subjects only increased intensity to a 
level that was comfortable for them.  
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Therefore it is possible to stimulate a training load for NMES that can be used 
by patients in their own home. It is also worth noting that in relation to the 
Empi-300PV™ that for the stimulation of large muscles that a symmetrical 
waveform should be used as stated in the accompanying handbook, however 
in the studies conducted by Bourjeily-Habr et al (2002) and the study by 
Zanotti et al (2003) asymmetrical waveforms were used. Hinghe and Sluka 
(2006) suggest that when a symmetrical waveform is used that there is no 
potential for a chemical reaction to occur under the electrodes, whereas with 
an asymmetric waveform there is potential for chemical reaction, which could 
result in discomfort for the patient. Although the study by Hinghe and Sluka 
(2006) found that there was no significant difference in perceived comfort.  
 
Length of intervention is also important most of the studies took place over a 
6-week period for 30 minutes a day. Bax et al (2005) illustrate the validity of 
this protocol by reporting that following a systematic literature review, that 
studies using NMES at high intensity for 3 weeks were not as effective as 
NMES conducted at lower intensities for a training period of up to 8 weeks 
(generally frequencies between 30-100Hz are recommended). Therefore a 
training period of 4-6 weeks should give reliable results; the waveform 
adopted was not specified. Many patients experiencing an exacerbation take 
a long time to recover, therefore rehabilitation and NMES need to be tailored 
to fit this timeframe.  
 
Recovery from acute exacerbation 
Quality of life recovery from an acute exacerbation appears in two phases, an 
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initial fast improvement in the first four weeks; and a second slower 
progression which can take up to several months the greatest improvements 
in the Saint Georges Respiratory Questionnaire were noted in the first 4 
weeks 8.9 (14.6) units, however this was a greater improvement than that 
noted over the next 4 months due to a significant improvement between 
weeks 4-12, 4.1 units (95% CI 2.2 to 5.9, p<0.0001) (Spencer and Jones 
2003).  
 
All of the aforementioned studies utilised NMES for patients with stable 
disease. This study will recruit patients when admitted to hospital with an 
exacerbation of their disease. Murphy et al (2005) suggest the principle of 
rehabilitation medicine is that early intervention can improve mobility and 
prevent muscle atrophy; their study concluded that it is useful for COPD 
patients to commence rehabilitation as early as possible.  
 
Value of Intervention During Exacerbation 
Man et al (2004) advocate the introduction of early rehabilitation by 
suggesting that despite optimum medical treatment, when discharged patients 
take a long time to regain baseline levels of functioning It has been illustrated 
by previous studies that NMES can be effective in maintaining physical 
capacity as an adjuvant therapy for those with stable disease; therefore it is 
feasible to assume that it could be of benefit if incorporated into early 
rehabilitative strategy for those suffering an exacerbation. This could not only 
provide scope for further research but also implement changes in practice to 
benefit the long term care of COPD.  
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The hypothesis for this study is that NMES is effective in maintaining 
peripheral muscle strength during an exacerbation of COPD. The null 
hypothesis for this study is NMES will not be effective in contributing to the 






Prior to commencing the study ethical approval was granted by the NHS 
Research Ethics Committee and NHS Research and Development (appendix 
11). All patients considered for participation in the study were admitted to 
hospital with an exacerbation of their COPD. A sample of twenty patients 
were randomised into a treatment or control group using a sealed envelope 
method. Informed consent (appendix 8) was sought from all patients involved 
in the trial. Patients were not considered for the study if they had any 
contraindications to the NMES unit for example if they had a pacemaker fitted. 
Patients’ consultants were informed of participation (appendix 9) and 
information sheets were supplied (appendix 10). Appropriate patients were 
supplied with information sheets on the first working day after admission, and 
were consented 24 hours after.  
 
Study Design 
A randomised controlled single blind trial was conducted to examine the 
effects of NMES on physical capacity in patients suffering from an 
exacerbation of their COPD. All patients were informed that they would be 
randomised into a treatment group using a therapeutic NMES regimen, or into 
the control group who would receive a ‘sham’ NMES technique at sub-
therapeutic levels, patients would not know which group they were in, 
however they would know that there were two groups. The author of the study 
was not aware of which group patients were allocated into, although two other 
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pulmonary rehabilitation practitioners were not blinded to the patient 
allocation. All patients were evaluated at the beginning of the study, on 
discharge from hospital; and they were then recalled 4 weeks after 
commencing (4 weeks after the day of recruitment) the study for follow-up 




Initial evaluation consisted of pulmonary function tests, an ISWT and 
measurement of quadriceps strength by strain gauge measurement. MRC 
scores were also taken, patients were asked to rate their MRC score in their 
usual state prior to admission to hospital.  Patients were also given the HADS 
and CRQ questionnaires to complete in their own time. Patients were asked 
to wear an activity monitor during their stay in hospital, if the admission was 
prolonged the monitor was to be worn up to a week (appendix 5).  
 
BMI 
Patients consented into the trial were asked to submit their height 
(centimetres) and weight (kilograms) using Seca™  weight chair, in order to 
calculate their BMI, or values were taken from recent medical notes.  
 
Pulmonary Function Tests  
Pulmonary function tests were performed by Spirometry, FEV1 and FVC 
measurements were taken. Participants were asked to perform three maximal 
forced expiratory breaths; these were taken while the patient was seated. The 
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spirometer used was the Micro Lab™ by Micro Medical Limited™.   
 
Exercise Tolerance 
In order to assess exercise tolerance, an ISWT was performed by those able, 
their dyspnoea and perceived exertion were assessed using the Modified 
Borg Score. As standard practice oxygen saturations were monitored 
throughout the ISWT using the Konica Minolta Pulsox 3™. Supplemental 
oxygen was provided for those who required it; if on long term oxygen 
therapy, or prescribed it while in hospital. Patients were asked to walk the 10 
metre course and asked to adjust their pace as the audible cues dictated for 
as long as they could. A 10-metre course was set out using string between 
two cones. The compact disc of audible cues was commenced and the patient 
started to walk with an assistant between the cones and then waited at the 
other cone for the audible cue before returning to the other cone. The test was 
ended if the patient could no longer keep up with the audible cues or if they 
themselves stopped due to fatigue or dyspnoea. If able, patients completed 
an ISWT on commencing the trial, again on the day of discharge from 
hospital, and when recalled at 4 weeks. If tolerated patients completed a total 
of 3 ISWT’s. Only standard encouragement was given, and the pulmonary 
rehabilitation practitioners completed the walks in a standard manner; they 
walked with the subject and gave them cues on when to walk and when to 
wait until the audio cue had sounded. 
 
Quadriceps Strength 
The Patients quadriceps strength was assessed using a strain gauge; a 
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dynamometer based on a Vernacare commode chair™ and Kern electrical 
balance unit™. The unit was calibrated by holding down the on/off button 
when the unit was switched on and checking that the readout was zero prior 
to the subject commencing the procedure. The procedure entailed patients 
sitting on the commode chair and pushing themselves back as far as possible 
to maintain good posture and ensure that the leg was hanging freely (90° hip 
and knee flexion). The patient was then strapped in and asked to keep their 
hands in their lap and not on the arms of the chair. A strap was secured 
around the leg and the patient was asked to extend their leg out as hard as 
possible and hold it during a count of three, then to relax; this was repeated 
five times, only on the patients strongest leg, corresponding to which hand 
they use.  
 
The Kern™ unit possessed a hold button which was pressed when the 
subject had kicked out their leg and the readout had stabilised, therefore 
when a plateau had been reached the measurement was taken. The initial 
strain gauge measurements were in kilograms in order to convert this to 
Newton metres values were multiplied by 9.087. The mean average of the five 
measurements was taken for the purposes of this experiment. Patients were 
given standard encouragement only; prior to the last of the five measurements 
they were encouraged to make an extra effort. 
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Strain gauge chair 
 
Activity Monitoring 
During their stay in hospital patients were requested to wear an activity 
monitor (Bodymedia Sensewear Pro2™).  The monitor was worn on the right 
arm around the bicep muscle. The monitor acts as a metabolic monitor 
displaying Total Energy Expenditure (TEE), Active Energy Expenditure (AEE), 
Metabolic Equivalents (METS), number of steps taken, Physical Activity 
Duration (PAD), sleep duration and time spent lying down, these are 
displayed using Sensewear™ professional software. The only times this was 
to be removed was when bathing, and when daily administration of NMES 
was taking place in order to minimise the electrical interference. For the 





Patients were also asked to rate their dyspnoea on the MRC scale (MRC 
2007) and the HADS (Zigmund and Snaith (1983) and self-reported CRQ 
(Guyatt et al 1987) were given out for patients to complete (see appendices). 
 
On Discharge from Hospital 
When a patient was ready for discharge they were again asked to repeat the 
ISWT and the quadriceps strength measurements were taken. Patients were 
supplied with their NMES unit, spare pads and batteries; and also a diary 
sheet for them to keep a record of intervention. They were supplied with the 
telephone number of the hospital in case of any problems and reassured that 
they would be phoned on at least a weekly basis to check progress; 
information sheets were also given (appendix 6). This intermediate data was 
not collected if patients were discharged unexpectedly following the collection 
of baseline data, or if the patient was an in-patient for the entire study. 
 
4-Week Follow-up 
At the end of the four-week period patients were recalled to complete follow-
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up data. The ISWT and quadriceps strength measurements were repeated. In 
addition to the physical tests patients were given follow-up CRQ (Appendix 7) 
and HADS questionnaires to complete. Patients were asked if they would like 
feedback at the completion of the study and then discharged. 
 
NMES Protocol 
The machine used for the trial was the EMPI 300PV™. The unit comprises 
four surface patch electrodes two for each leg, one to be applied to the top of 
the quadriceps muscle and one for the bottom of the muscle. The size of the 
pads was 5×9cms. On commencing the trial patients were supervised until 
able to apply the pads correctly and use the controls, they were also provided 
with an information sheet for guidance. 
 
Treatment Protocol 
The treatment protocol was based on the regime adopted by Bourjeily-Habr et 
al (2002). This was comprised of a pulse rate of 35pps, symmetrical biphasic 
waveform, using a synchronous cycle with an on time of 10 seconds and an 
off time of 5 seconds. The timer was set at 30 minutes. This would be 
continued on a daily basis for a 4-week period. The rationale for this regimen 
was that it was the programme proposed for the treatment of disuse atrophy, 
and can be used for larger muscle groups. A frequency of 35Hz was used as 
opposed to 50Hz as used in the Bourjeily-Habr et al (2002) research because 
the previous studies which selected a sample as disabled as the sample in 
this current study used a frequency of 35Hz. Patients were given guidance on 
how to apply the device and requested to increase the amplitude to a 
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tolerable level or until they could see a visible contraction of the muscle. 
Patients in the treatment group were also advised to take a walk each day 
until constrained by their symptoms. 
 
Control Protocol 
The control regimen was based on a conventional Transcutaneous Electrical 
Nerve Stimulation (TENS) setting pulse rate 100Hz, synchronous channel 
cycling, and symmetric biphasic waveform. The timer was also set at 30 
minutes and patients applied the unit daily for a 4-week period. The subjects 
were asked to increase the intensity to a tolerable level or until they could feel 
a tingling sensation. The reason TENS was chosen as the ‘sham’ technique 
was in case two subjects, one from each group began to discuss the trial it 
would be obvious to them which group they were in if one stated they had to 
increase the intensity and the other had been advised not to change the 
settings. The control group also took part in activities advised by the staff in 
the Active Therapy Unit such as using pedals or daily supervised walks. Both 
groups were advised to undertake physical as able, when visited by the 
research team subjects would be asked if they wished to be accompanied on 
a walk as far as possible until constrained however this was not compulsory 
only advised, all other aspects of care were comparable for both groups.   
 
Exclusions 
Patients were excluded from the trial if they were re-admitted to hospital 
during the trial period, and therefore would not have used the unit, or if they 




The results will be analysed using the Statistics Package for Social Sciences 
(SPSS) issue 15.0. Baseline characteristics of the two groups will be 
expressed as the mean Standard Deviation (SD). Comparison between the 
two groups will be expressed as the mean difference with a 95% Confidence 
Interval (CI), in relation the FEV1, ISWT and Strain Gauge (SG) (quadriceps 
strength) measurements. Between the groups baseline data will be subjected 
to an independent T-test. To compare pre- and post treatment data within the 
group a paired T-test will be used. Non-parametric tests will be used to 
analyse the data generated from the perception scales and questionnaires. 
The non-parametric tests used will be the Wilcoxon signed ranks test, 
followed by the Friedman test to compare group data. Strain gauge and 
shuttle walk data collected at the three time intervals will be analysed using 
repeated measures ANOVA. The primary outcome measures will aim to 
ascertain whether physical capacity measured by SG and ISWT data is 
maintained throughout the 4 week trial period. The level of statistical 
significance was set at p<0.05, however outcomes which reach a level of 
statistical significance will be viewed with caution due to the possibility of type 
Ι errors. Due to recruitment difficulties individual plots of data are also 
reported for measures of strength and performance in the ISWT. No formal 
power calculations have been employed. This can be viewed as a pilot study 
collecting data to inform a wider study looking at physical interventions during 
an exacerbation. The aim is to explain feasibility and effectiveness in 
maintaining physical capacity during an exacerbation of COPD.  
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Results 















Age (years) 66.4 (6.8) 72.7 (9.9) P=0.69 
Gender (M/F) 4/4 7/5  
FEV1 0.80 (0.25) 0.82 (0.45) P=0.91 
BMI (kg/m2) 29.1 (11.2) 22.9 (6.2) P=0.13 
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O2 sats (%) 
resting 
92.6 (3.2) 92.4 (3.9) P=0.92 
ISWT (metres) 
Baseline 
10.0 (17.3) 20.9 (35.7) P=0.47 
Quads strength 
(Nms) baseline 
170.9 (94.5) 109.4 (50.9) P=0.79 
Table 1 
 
BMI= body mass index, Kg/m2= kilograms per metre squared, O2 sats= 
oxygen saturations, Nms= Newton metres. 
 
The baseline characteristics are represented in table 1. There were no 
significant differences between the groups for the reported measures, on 
average the group has severe airways disease FEV1  mean average of 30.4% 
GOLD group III to IV. There was a between group difference in the FEV1 
measurements of the control (0.80L) and experimental (0.82L) groups. The 
mean BMI for the group is 24.8 Kg/m2, however the control group had a 
slightly higher BMI than the experimental group (29.1 compared to 22.9). 
Resting oxygen saturations were low for both groups.  6 patients out of the 
sample of 20 who were able to complete the ISWT at baseline, used 
supplemental oxygen of between 24-28%. The ISWT was very low for both 
groups. The difference between groups at baseline was not statistically 
significant. It was difficult to compare groups due to the small amount of data 









Paired data Mean 
difference 




40.0 57.5 -81.7 to 1.2 
ISWT 
discharge to 
ISWT 4wks  
29.2 22.9 5.1 to 53.2 
 ISWT baseline 
to ISWT 4wks 
55.6 67.3 -111.9 to 0.6 
SG baseline  to 
SG discharge  
33.3 59.5 -79.0 to 12.5 
SG discharge 
to SG 4wks  
-22.0 36.1 -22.8 to  66.7 
SG baseline  to 
SG 4wks  
9.1 15.5 -22.0 to 3.9 
Table 3 
Paired data Mean 
difference 
SD CI lower CI upper 
ISWT baseline 
to ISWTm 4wks  
105.0 117.3 -291.7 to 81.7 
ISWT 
Discharge  to 
ISWT 4wks 
56.7 55.1 -281.3 to 254.6 
ISWT baseline 
to ISWT 4wks 
92.0 98.8 -214.7  to 30.7 
SG baseline to 
SG discharge  
118.6 52.6 -591.4 to 354.2 
SG discharge  
to SG 4wks  
0.6 18.9 -170.8 to 169.5 
SG baseline to 
SG 4wks 




Tables 2 and 3. SG=strain gauge in Newton metres ISWT= shuttle walk 
metres SD=standard deviation CI=confidence interval (95%) 4 wks follow up 
data. 
 




The data generated from strain gauge measurements of quadriceps strength 
was normally distributed. During the in-patient stay the maximum strength 
increased from 120.0 (SD 56.2)Nm to 153.1 (SD 73.4)Nm p=0.13 (df 8) (n=9) 
although this was not a significant increase (p>0.05) in quadriceps strength, 
equally there was no decline observed. From baseline to discharge from 
hospital there was a mean increase of 33.3 (SD 59.5)Nm (95%CI –79.0 
to12.5).  
Control group 
Only a small number of patients completed the control period n=5, inevitably 
data analysis has been compromised, therefore results reported for the 
control group will reflect general trends. There was an increase in quadriceps 
strength during the in-patient period the mean increase was 118.6 (SD 
52.6)Nm (95%CI –591.4 to 354.2). 
 
Discharge to 4 weeks 
Experimental group 
From discharge to 4 weeks there was a mean decline of 22.0 (SD 36.1)Nm 
(95%CI –22.8 to 66.7). This was not statistically significant p>0.05. 
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Control group 
There was a small increase in quadriceps strength from discharge to 4 weeks 
of 0.6 (SD18.9)Nm (95%CI –170.8 to 169.5) this was not statistically 
significant p=0.97. 
 
Baseline to 4 weeks 
Experimental group 
Comparing the baseline data with the data collected after 4 weeks of NMES 
using a paired t-test, the maximum quadriceps strength had marginally 
improved in the experimental group. From baseline to 4 weeks there was a 
small mean increase of 9.1 (SD 15.5)Nm (CI –22.0 to 3.9), however The t test 
data in relation to quadriceps strength noted that Levene’s test for equality of 
variances was not significant p>0.05, equality of means data also failed to 
generate p>0.05. (Raw data used for paired t test illustrated in table 2, raw 
strain gauge data shown in table 4).  
 
Control group 
The baseline mean quadriceps strength was 170.9 (SD 94.5)Nm increasing to 
207.8  (SD 107.6)Nm p=0.526 (df 3), translating to an overall mean increase 
of 36.9Nm from baseline to 4 weeks. There were no significant increases in 
quadriceps strength using the paired t-test (fig 1) from baseline to 4 weeks 
mean increase 37.5 (SD 104.6)Nm (95%CI -204.0 to 129.0) p=0.53.  
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 fig 1 
 fig 2 
 
Group comparison 
Comparing the groups is difficult due to the small sample size in the control 
group. A repeated measures ANOVA noted that there was a significant 
difference dependent on treatment group F(1.51)=10.10 p<0.5, there was no 
time/group interaction. However these results cannot be definitively concluded 
upon due to the small sample size tested. Figures 3 and 4 illustrate each 
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patient’s strain gauge measurements at the three time intervals; the missing 
data shows how difficult statistical analysis was. 
 baseline Discharge 4 weeks 













 fig 3 
 fig 4 
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Effect of NMES on exercise capacity 
In-patient results 
Experimental group 
For the experimental group the mean baseline ISWT was 21.0 (n=8) (SD 
37.8)m. On discharge from hospital the mean had increased to 61.0 (SD 
49.0)m (mean increase 40m) (fig 5). Although the increases were not 
consistently statistically significant a paired samples t-test illustrated a strong 
trend towards improvement, as baseline to discharge mean increase 40.0m 
p=0.06 (df=9) (95%CI –81.7 to 1.1); 
Control group 
In the control group the baseline mean ISWT was 10.0 (n=5) (SD 20.0)m, at 
discharge the mean distance was 115.0 (SD 109.1)m (mean increase of 
105m) (CI –291.7 to 81.7). A paired samples t-test found no significant 
increase in exercise capacity from baseline to discharge p=0.171 (df=3) 
(95%CI –291.7 to 81.7). 
 
Discharge to 4 weeks 
Experimental group 
The increase in exercise capacity from discharge from hospital to 4 weeks 
was significant p=0.03 (df=5) (95%CI 5.1 to 53.2). 
Control group 
From discharge to 4 weeks the increase in ISWT was not significant p=0.850 




Baseline to 4 weeks 
Experimental group 
At 4 weeks the mean had further improved to 70.6 (SD 60.1)m from baseline 
to 4 weeks) (fig 8).  From baseline to 4 weeks mean increase 55.6m p=0.05 
(df=7) (95%CI –111.9 to 0.6). The data was normally distributed apart from 
the baseline ISWT as there were several subjects unable to complete the test. 
Levene’s test for equality of variance demonstrated p>0.05, the t test for 
equality of means also demonstrated p>0.05 in relation to ISWT data.  
Control group 
At 4 weeks the mean distance was 100.0 (SD 93.0)m (a mean increase of 
90m from baseline to 4 weeks), from baseline to 4 weeks mean increase 
92.0m p=0.11 (df=4) (95%CI –214.7 to 30.7). Individual patient data see fig 6. 
 
 Fig 5. 
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 fig 6 
Group comparison 
A repeat measures ANOVA noted that between groups F=0.380 and this did 
not generate a level statistical significance p>0.05.  Again it is difficult to make 
any firm conclusions from this data due to the small sample represented. For 
the effect of time F=5.137 therefore the effect of time was not statistically 
significant. (Raw ISWT data shown in table 5). 














Figures 5 and 6 illustrate each subjects shuttle walk tests results at each of 
the time intervals, again the lack of data makes it difficult to analyse and draw 





Effect of NMES on activity 
For the first 4 days of the study patients were asked to wear an activity 
monitor. Overall there was a trend for recorded activity to decline 
independently of any intervention.  An independent samples t-test found no 
significant difference in number of steps taken between the control and 
experimental groups. On day 1 the mean number of steps taken for the 
experimental group were 530 (SD 609.3), the control group took 634 (SD 
494.4) steps. By day 4 the experimental group had taken a mean number of 
423 (SD 623.3) steps, whereas the control group took 447 (SD 441.2) steps.  
 
Day 1-4 comparison 
An independent samples t-test of the number of steps taken found that for day 
one p=0.812 df=6; by day five p=0.753 df=3. This illustrated no statistically 
significant difference. (fig 7 demonstrates number of steps against days, 
experimental group n=5 control group n=3). 
 
A repeat measures test also found no significant difference in number of steps 
taken within the groups. For the control group for days 1 to 4 p=0.62 (df=1) 
(n=2). For the experimental group for days 1 to 4 p=0.38 (df=3) (n=4). For the 
t-tests the data up to day 4 was used only as by day 5 n=1 in the control 
group. A Pearson correlation also found no relationship between baseline 
ISWT distances and the number of steps taken in the first three days the 
activity monitors were worn, day p=0.23, day 2 p=0.28 and day 3 p=0.68.    
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  fig 7. 
Effect of NMES on anxiety and depression (HADS scores). 
Experimental group 
Anxiety and depression data was collected at baseline and 4 weeks only. The 
mean depression score at baseline was 8.3 (SD 3.9). The mean anxiety score 
at baseline was 11.0 (SD 4.1). At 4 weeks the mean anxiety score was 10.3 
(SD 3.0) and the mean depression score was 7.9 (SD=2.0). A Wilcoxon 
Signed Ranks Test found no significant difference in HADS scores, (anxiety 
p=0.311, depression p=0.550) (fig 8). 
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 fig 8. 
 
Control group 
 For the HADS questionnaire the mean anxiety score in the control group at 
baseline was 10.7 (SD 4.3), and the mean depression score was 7.8 (SD 2.0). 
At 4 weeks the mean anxiety score was 9.8 (SD 4.8). The mean depression 
score was 8.5 (SD 3.5). A Wilcoxon Signed Ranks Test found no significant 
difference in the HADS scores of the control group (anxiety p=0.10) 
(depression p=0.66). Therefore there was no significant difference in the 
levels of anxiety and depression in the control group from baseline to 4 weeks 





A Friedman test found no significant differences in HADS scores between the 
control and experimental groups. For the anxiety scores p=0.32, and for the 
anxiety group p=1.0.  
 
Health related quality of life (CRQ-SR) data. 
Experimental group 
In the experimental group at baseline the mean dyspnoea score was 2.3 (SD 
1.3), the mean fatigue score was 2.8 (SD 1.0), the mean emotion score was 
3.5 (SD 1.2), and the mean mastery score was 3.3 (SD 1.3). At 4 weeks the 
mean dyspnoea score was 2.9 (SD 1.3), the mean fatigue score was 2.8 (SD 
1.3), the mean emotion score was 3.7 (SD 1.2) and the mean mastery score 
was 4.2 (SD 1.1). 
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A Wilcoxon Signed Ranks Test noted that there was no statistically significant 
increase in score over the 4 week period; (dyspnoea p=0.61, fatigue p=0.95, 
emotion p=0.44, mastery p=0.11). Therefore there were no significant 
increases in health related quality of life over the 4 week trial period, however 
some clinically significant results were gained, where scores increased by 0.5 
mastery domain (fig 8). 
 
Control group 
The mean scores in the dyspnoea domain at baseline was 2.3 (SD 0.6), the 
mean fatigue score was 2.1 (SD 0.5), the emotion score was 3.1 (SD 0.4) and 
the mastery score was 3.1 (SD 1.1). At 4 weeks the mean dyspnoea score 
was 2.6 (SD 0.2), the fatigue score was 2.6 (SD 0.8), the emotion score was 
3.6 (SD 1.1) and the mean mastery score was 3.5 (SD 1.5). There was no 
significant difference in any of the four domains (dyspnoea p=1.00, fatigue 
p=0.13, emotion p=0.23, mastery p=0.23). However there were clinically 
significant improvements in the fatigue, emotion and mastery domains (scores 








Paired samples Mean changes in CRQ results from baseline to 4 weeks 












CI-1.0 to 0.7 
-0.8 
(SD1.2) 





CI-2. to 1.7 
-0.7 
(SD0.9) 
CI-1.8 to 0.5 
-0.7 
(SD1.1) 
CI-2.1 to 0.7 
-0.4 
(SD0.8) 
CI-1.4 to 0.6 
Table 6 
  . 
 fig 10. 
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  fig 11. 
Group comparison 
A Friedman test generated statistically significant results in the emotion 
domain only (p=0.03) , this could be a type 1 error.  In the dyspnoea domain 
p=0.53, p=0.29 in the fatigue domain and p=0.11 in the mastery domain.   
 
Effect on MRC and Borg scoring 
Experimental group 
Mean MRC at baseline was 4.8(SD 0.6), mean MRC at 4 week follow up was 
4.7 (SD 0.7). A Wilcoxon signed ranks test found no significance between the 
experimental groups MRC scores from baseline to 4 weeks (p=1.00) 
 
The mean resting Borg score for the experimental group at baseline was 2.4 
(SD 1.2) at 4 weeks the mean was 1.0 (SD 1.0). There was no significant 
improvements in resting Borg score (p=0.32). 
 
The mean Borg breathlessness at baseline was 3.9 (SD 0.7) at 4 weeks the 
mean was 3.8 (SD 0.8). There was no significant difference in the 
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breathlessness scores; following ISWT from baseline to 4 weeks p=1.00. The 
mean Borg exertion score at baseline was 9.1 (SD 6.2), at 4 weeks the mean 
was 13.0 (SD 4.0). At the end of 4 weeks there was no significant 
improvement in Borg exertion scores p=0.37.     
 
Control group 
At baseline the resting mean Borg score was 1.6 (SD 1.8) at 4 weeks the 
mean was 3.0 (SD 2.8). A Wilcoxon signed ranks test found no significant 
improvement in scores (p=0.66) 
 
The baseline mean Borg breathlessness score was 2.5 (SD 0.7), at 4 weeks 
the mean was 4.3 (SD 0.6). The mean Borg exertion score at baseline was 
8.8 (SD 11.7), at 4 weeks it was 14.0 (SD 1.0). There was no significant 
improvement for either group in perceived breathlessness or perceived 
exertion (results illustrated in fig 12 and fig 13).    
 
At the beginning of the trial the mean MRC was 4.6 (SD 1.1) at 4 weeks the 
mean was 3.8 (SD 0.8). There was no significant improvement in MRC scores 
from baseline to 4 weeks p=0.33. 
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 fig 12.  
 
 





This is the first study to describe the effects of NMES during an acute 
exacerbation of COPD. It was delivered within the context of an established 
Active Therapy Unit, which has been set up within the Pulmonary 
Rehabilitation department at Glenfield Hospital, University Hospitals Leicester 
NHS Trust. 
 
The main findings of the study were that there were no baseline differences 
between the control and experimental groups. There was also no between 
groups differences in the level of activity taken. Throughout the trial period 
there was an increase of 9.1 (SD15.5)Nm in quadriceps strength. However 
the control group also demonstrated an increase in quadriceps strength (37.5 
SD104.6)Nm. Neither of these increases generated a level of statistical 
significance. Exercise performance as measured by ISWT was improved for 
both groups over the 4 week period. For the experimental group the mean 
distance walked at discharge from hospital was 61.0 (SD49.0)m, from 
discharge to 4 weeks there was a small significant increase to 70.6 
(SD60.1)m p=0.026. Distances covered in the ISWT by the control group were 
also improved. The mean distance at discharge was 115.0 (SD109.1)m there 
was then a small decrease at 4 week follow-up (100.0 SD93.0)m.  No 
statistically significant improvements in health related quality of life were 
observed. There were clinically significant improvements noted in the mastery 
domain of the CRQ-SR. 
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 The problems with recruitment in the current study make it difficult to draw 
any firm conclusions from the control group data. Therefore this discussion 
will incorporate the control group data but mainly focus on the results of the 
intervention group. Overall this current study noted that by encouraging 
patients to walk and by using NMES quadriceps strength was not only 
maintained, but also improved and ISWT results also illustrated a strong trend 
towards improvement. 
 
The ATS/ERS (2006) state that pulmonary rehabilitation has been recognised 
as a cornerstone in the management of COPD patients. However they note 
that further research is required to optimise the effectiveness of rehabilitation, 
this includes defining the effects of the non-volitional components of 
rehabilitation; for example hormonal therapies and supplemental oxygen. 
NMES could be considered one of these strategies that may be a particularly 
important adjunct to rehabilitation during an acute exacerbation where 
patients have ventilatory limitations. 
 
Two previous papers by Spruit et al (2003) and Pitta et al (2006) have 
identified a decline in physical performance during an acute exacerbation. 
Both papers reported a decline in quadriceps force during hospitalisation. 
Both groups in this current study appeared to benefit from some intervention. 
The experimental group had an active stimulation profile and supervised 
walking, whilst the control group had a sham NMES intervention plus 
supervised walks, or pedals. This is an important difference between the 
current study and those reported by Spruit et al (2003) and Pitta et al (2006) 
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where no intervention was offered. Pitta et al (2006) noted a positive 
correlation between time spent in weight bearing activity and quadriceps force 
at day 8 of hospital admission. Therefore it would appear that any modest 
form of activity may be of value to the individual in preserving quadriceps 
strength during the acute phase of an acute exacerbation.   
 
Muscle strength 
NMES can be used to improve the fundamental properties of muscles. 
Previous research has found that NMES can be of use as an adjuvant therapy 
for COPD patients during stable disease. In comparison to previous studies 
utilising NMES was quite difficult as it was used in an acute setting where 
using NMES was not an established therapy in COPD. A study by Bourjeily-
Habr et al (2002) conducted research using NMES they found that after 6 
weeks of NMES that quadriceps strength had improved significantly in the 
treatment group from (44.7 (6.5) to 55.2 (6.6) Nm p=0.004). The current study 
noted a mean increase in quadriceps strength from baseline to discharge from 
hospital of 33.3 (SD 59.5)Nm (95%CI –79.0 to 12.5) but this was not a 
statistically significant increase (p>0.05). The control group also demonstrated 
a non statistically significant increase in quadriceps strength during the in-
patient stay, mean increase 118.6 (SD 52.6)Nm (95%CI -591.4 to 354.2) 
perhaps more importantly a significant decline in function was not detected.  
 
The study by Neder et al (2002) also noted trends towards improvement in 
quadriceps force following NMES, however these improvements were not 
significant, (from 64.4 (32.3) to 91.8 (29.3)Nm), again these measurements 
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appear to be very low compared to the current study, this could possibly be 
due to how disabled their sample was (mean predicted FEV1 38.0-39.5%), 
although this could be related to the measurement technique used. Zanotti et 
al (2003) used a sample of patients in intensive care, their sample undertook 
active limb mobilisation with or without NMES, they found that after 28 days 
both groups illustrated significant increases in muscle strength, the group that 
also used NMES was able to further increase that strength (from 2.16 ±1.02 
vs 1.25±0.75, p=0.02 using muscle strength scoring system 0-5). They 
illustrated a decrease in the number of days needed to transfer from bed to 
chair (10.75 ± 2.41 days vs 14.33 ± 2.53 days for the group who did, and did 
not respectively use NMES p=0.001) Although the patients in this current 
study were not in intensive care there is comparison to be made, as patients 
in this study were hospitalised for an average of 7-10 days which is as long as 
was needed to progress towards transferring from bed to chair, this decrease 
in time taken to transfer from bed to chair also correlates with the increase in 
quadriceps strength reported during the patients in hospital stay. It is however 
difficult to directly compare these favourable results to this study as muscle 
strength was calculated using a scoring system as opposed to using objective 
operator resistance measurement.  
 
The sample taken by Vivodtzev et al (2006) were the most comparable to the 
sample used for this study in terms of disability, as the mean predicted FEV1 
was 30±3% (30.4% for this particular study).  Vivodtzev et al (2006) reported 
that in their study at 4 weeks both the control and treatment groups displayed 
a significant increase in maximal volitional contraction of the quadriceps, since 
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both groups were undertaking traditional rehabilitation. In the rehabilitation 
plus NMES group there was a 35% increase in maximum volitional 
contraction (97±71 contractions while seated on a dynamometer), in the 
control group there was an increase of 14% (36±34 contractions) p=0.03. 
Vivodtzev et al (2006) found significant improvements in quadriceps strength, 
and significant improvements in the 6-minute walking test. This current study 
is broadly in line with their findings, noting improvements in quadriceps 
strength but these were not significant, and ISWT increases which displayed a 
trend towards significance.  
 
Dal Corso et al (2007) recruited a population that is the most diverse to the 
current study, and found no significant increases in quadriceps strength 
(93.8±43.7 to 103.2±50.6Nm) following 6 weeks NMES.  This population were 
in relatively good health therefore less improvement might be achieved by 
involuntary training, voluntary training alone may have been more beneficial.  
 
It could have therefore been hypothesised that this current study would 
potentially secure significant increases in quadriceps strength as the sample 
were all severely impaired and suffering exacerbation, however the results do 
not illustrate this; reasons for this are most likely due to the small sample size 
used, and the fact that the control group did not have imposed bed rest, and 
were encouraged to mobilise; or possibly that the NMES was effective in the 
period from baseline to discharge from hospital but then improvement during 
the ‘home period’ was not as pronounced. This current study incorporated the 
use of diary cards in order to monitor compliance and improve motivation; 
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however analysis of the data was beyond the scope of the study. Although not 
all patients completed these cards and it is difficult to assess the accuracy of 
these as their completion during the study was not monitored.  
 
Exercise Capacity 
In terms of exercise capacity the experimental group did not illustrate 
statistically significant improvements over the 4-week period, however in the 
period from discharge from hospital to 4 weeks the improvement was 
statistically significant. It is however worth noting this statistical significance 
with caution, as it could be attributed to a type Ι error, as an assumption can 
be made that since so many statistical tests were conducted there is a chance 
one will reach a significant level. Boujeily-Habr et al (2002) noted a significant 
increase in physical capacity (p=0.007) the mean shuttle walk distances 
increased from 185.2 (21.8)m to 254.4 (30.4)m. Whereas for this study at 
baseline the mean distance was 21.0 (37.8)m which increased to 70.6 
(60.1)m at 4 weeks. For the control group for the same period the mean 
baseline was 10.0 (20.0)m increasing to 100.0 (93.0)m at four weeks. Direct 
comparisons cannot be made as the groups in the current study and 
Bourjeily- Habr et al (2002) study were not similarly disabled. Natural recovery 
from exacerbation was also not accounted for.     
 
Man et al (2004) recruited a sample of 42 patients admitted to hospital with an 
acute exacerbation. They were randomised into either an early rehabilitation 
group (within 10 days of discharge) or allocated into a usual care group. 24 
hours prior to discharge patients completed an ISWT. At discharge the 
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median ISWT for the usual treatment group was 115m and for the early 
rehabilitation group it was 120m. However when patients were reviewed at 3 
months post discharge the ISWT distances were 90 and 210m respectively. 
Man et al (2004) concluded that the patients who attended rehabilitation within 
10 days of discharge from hospital displayed clinically significant 
improvements in exercise capacity and health status at 3 months. This 
translated into 35.0% versus 57.1% readmission rate for the early 
rehabilitation group with fewer in-hospital days.  
 
The current study demonstrated overall increases in ISWT distances up to 4 
weeks despite a mean decline of 12m from discharge to 4 weeks for the 
control group. This would seem to support the idea that early intervention is of 
benefit since even the control group did not remain completely sedentary. The 
argument remains what is the best form of intervention whether it be NMES or 
early pulmonary rehabilitation would require further research. The pattern of 
ISWT performance appears to be similar between the current study and that 
of Man et al (2004). Seemungal et al (2000) note that in their study of 
recovery following exacerbation, that peak expiratory flow rate was only 
recovered to baseline in 75.2% of patients at 35 days, for 7.1% of patients 
recovery to baseline had not occurred by 91 days. However this cohort of 
patients were all attending outpatients clinics but were not partaking in 
rehabilitation, this appears to illustrate natural recovery from exacerbation.  
     
Neder et al (2002) noted significantly higher exercise tolerance following 
NMES (p<0.01), although the exercise taken cannot be directly compared as 
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a cycle ergometer was used as opposed to the ISWT. A significant increase in 
6 minute walking distance (63±40m, p=0.01) was found for the experimental 
group by Vivodtzev et al (2006). The control group reported by Vivodtzev et al 
(2006) also displayed an increase in distance although it was not significant 
(increase of 30±38m p=0.07). These improvements could be attributed to the 
fact that both the experimental and control groups also undertook usual 
rehabilitation. 
 
Dal Corso et al (2007) found that NMES had no significant effect on 6 minute 
walking distances. One of their main findings noted that NMES had no 
discernable effect on muscle strength or walking capacity, although there 
were fibre changes at micro-structural levels. One reason that their findings 
did not concur with the aforementioned studies could be attributed to the 
sample used, as the sample taken by Dal Corso et al (2007) were all 
outpatients with mean predicted FEV1 measurements of 49.6±13.4%; 
compared with the current study whose experimental mean FEV1  predicted 
was 30.5 (SD 13.1)%, which although makes them moderately impaired 
means they were not as debilitated as the samples used in this research or 
the other papers reviewed. 
 
Quality of life 
This study found no significant difference in anxiety and depression levels at 4 
weeks following NMES; it also found that although there were no significant 
differences in CRQ data there were some clinically significant results. This is 
in comparison with the findings of Spencer and Jones (2003) who reported 
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significant improvements in the SGRQ at 4 weeks following exacerbation, and 
reported further improvements between 4-12 weeks. Man et al (2004) note 
that at 3 months following exacerbation there were significant improvements 
in all four domains of the CRQ for the early rehabilitation group. Therefore if 
the CRQ was repeated again from 4-12 weeks there may have been a 
significant improvement noted, or if the rehabilitation period had been 
extended. 
 
 Voll-Aanerud et al (2008) suggest that respiratory symptoms such as cough, 
dyspnoea and wheeze are more strongly associated with Health Related 
Quality of Life (HRQL) than pulmonary function. Therefore if this study had 
also looked at differences in respiratory symptoms in conjunction with the 
CRQ there may have been a more representative change in HRQL. Neder et 
al (2002) found that following NMES mean scores for the dyspnoea domain of 
the CRQ had improved compared with baseline (mean difference 1.4 (95% CI 
to 2.3); p<0.05). To assess HRQL Vivodtzev et al (2006) utilised the 28 item 
Maugeri Foundation Respiratory Failure Questionnaire (MRF-28). Despite this 
differing from the CRQ, it is comparable because like the CRQ it is disease 
specific and self-administered. After assessment using the MRF-28 Vivodtzev 
et al (2006) noted a significant decrease in the ‘dyspnoea in daily activities 
domain’ in the NMES group. This supports the clinically significant changes 
noted in this current study. This current study did not continually supervise 
patients once they were familiar with the NMES unit, however if patients had 
been more closely supervised or possibly always had a health professional to 
walk with them during the trial, or a home visit it could be speculated that 
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there could have been larger improvements in HRQL, although this would be 
time consuming for the research team.  
 
Bourjeily-Habr et al (2002) note a significant improvement in their 
experimental groups perceived exertion level from (12.7 (SD 0.64) to 10.1 (SD 
0.90) p=0.01), this differed from their control group whose improvement was 
not significant (12.8 (SD 0.88) to 12.6 (SD 0.76) p=0.79). In comparison 
Vivodtzev et al (2006) recorded their samples Borg dyspnoea scores for the 
experimental group, the pre treatment score was 6.5±2.3 and post 6.0±1.5 
this was not a significant improvement (p=0.39). In their control group the 
mean score was 5.0±2.9 and the post score was 6.0±2.6 (p=0.07), this is 
interesting as neither were statistically significant however both groups in the 
study by Vivodtzev et al (2006) took part in usual rehabilitation which did not 
significantly improve their dyspnoea or perceived exertion; despite this the 
authors reported that the experimental group reported improvements in their 
dyspnoea after completing health related quality of life questionnaires. 
 
The results in the current study illustrated no significant improvements in 
either the control or treatment groups’ perceived dyspnoea as measured by 
the MRC and Borg scores. It was also confirmed that there were no significant 
improvements in the patients’ perceived breathlessness or exertion from 
baseline to 4 weeks, for either the control or treatment groups. 
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Current study findings 
The findings of this current study do not necessarily reiterate the 
improvements in physical performance following NMES described by previous 
studies. However the hypothesis was not that patients would improve; but 
rather that physical capacity be maintained during an exacerbation. Patients 
used in this sample were chosen if admitted with an exacerbation. However in 
previous research patients were chosen in the absence of exacerbation. Only 
the study by Vivodtzev et al (2006) incorporated a sample of similarly disabled 
patients, although they were all recovering from exacerbation. This study did 
illustrate that physical capacity can be maintained during an exacerbation. It is 
difficult to attribute this maintenance solely to the NMES because the control 
group did not remain completely sedentary. In the clinical environment it is 
unethical to say to the experimental group that they must not undertake any 
physical exercise because it is widely known that physical activity is of benefit, 
although its benefit at the time of exacerbation is not known. Both groups 
were advised to complete a supervised walk each day as long as was 
tolerated; walking is aerobic activity which is not necessarily associated with 
an increase in quadriceps strength. If walking was declined pedals for use at 
the bedside were offered as an alternative. Therefore this study is unable to 
detect if any maintenance or improvement in physical capacity is due to the 
NMES protocol, or rather the provision of any type of intervention during the 
occurrence of exacerbation. 
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Physical capacity  
Pitta et al (2006) note that patients with a low activity level at one month 
following discharge were more likely to be readmitted during the year, this 
correlates with the time course of most NMES studies, which range from 4 to 
8 weeks. The sample of patients investigated in the Pitta et al (2006) paper 
were similarly disabled to those in the current study (mean FEV1  29-34% from 
day 3 of exacerbation to 1 month after). They found that patients had a low 
level of physical activity during and after hospitalisation, and that during the 
course of an 8 day in-patient period there was a significant reduction in 
quadriceps force (Nm98-90 day 3-8) of exacerbation . In contrast the current 
study noted the same low level of physical activity but not the significant 
decline in quadriceps force. If patient management aimed to encourage 
physical activity for this period whether NMES was incorporated or not 
readmission rates may decline, however a structured period of an intervention 
such as NMES may ensure patient compliance for up to a month following 
discharge.  
 
A further study by Pitta et al (2008) reiterated their previous findings by noting 
that during a 6-month rehabilitation programme after 3 months there were 
improvements in physical capacity, muscle force and functional status 
(p<0.05) reinforcing the need for promotion of physical activity. A Pearson 
correlation of the current study findings noted no significant correlation 
between number of steps taken in days 1-3 of admission and the distances in 
the baseline ISWT. Therefore if an intervention commenced early enough the 
baseline ISWT performance may be positively influenced. 
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 From the data collected from the activity monitors it is clear that the sample of 
patients in this study were very inactive, despite the monitors being very 
sensitive to any movement. One reason for this could be patients assuming 
the sick role when admitted, or not receiving enough information about the 
benefits of exercise. Further research could aim to find out if there is a 
correlation between HADS and CRQ scores and levels of activity, this could 
provide clues as to what are the barriers preventing patients partaking in 
physical activity. The use of walking aids such as ‘rollators’ may also affect 
the number of steps taken by patients, as their results were so low. It is 
possible that the activity monitors were not sufficiently sensitive to register the 
movement of the patients when their arms were static holding on the rollator.   
 
Limitations 
This pilot study demonstrates it is feasible to employ NMES technology but 
there have been several difficulties with the study. As illustrated by previous 
studies of this nature the major limitation of this study is its small sample size, 
which means statistical results achieved lack the power to evaluate just how 
beneficial NMES could be. Recruitment could be improved by educating staff 
to the potential benefits of NMES, however there will always be reluctance as 
patients are aware that they may be in a control group not using a therapeutic 
technique. When undertaking research in a small unit recruitment can be 
hampered by patients taking part in other research trials. More robust results 
should be gained from the wider study that is in progress incorporating a 
larger sample. Another limitation is the fact that efficacy cannot be solely 
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attributed to NMES because it would be unethical to advise the experimental 
group not to undertake any physical activity during the trial period.  
 
If NMES was incorporated into rehabilitation an analysis of cost effectiveness 
would need to be undertaken, it does however seem feasible to suggest that if 
a 4 week period of NMES can assist in preventing subsequent readmission to 
hospital then it would be worth it; not only financially but in terms of quality of 
life for the patient. Garcia-Aymerich et al (2003) suggested that there is an 
association between physical activity and a reduced readmission to hospital 
following COPD exacerbation, and that this has potential ramifications for 
rehabilitation and its adjuvant therapies. Since patients hospitalised with an 
exacerbation are so inactive during admission and after discharge from 
hospital, efforts to enhance activity at this time should be an aim of the 
disease management of COPD (Pitta et al 2006). 
 
As previously mentioned it is also difficult to make this trial completely 
controlled as it would be unethical to expect patients to remain bed bound for 
the duration of the trial to allow any improvements in the treatment group to 
be attributed to the NMES, although this is standard practice in many wards 
across the UK. There are however encouraging results to be gained from the 
organisation of active therapy units where it is customary to offer physical 
therapy advice. It was also difficult to design a protocol for the control group, it 
would seem valid to use NMES settings for both groups but advise the control 
group not to touch the controls to increase the intensity, however if for 
example there were members of each group in close proximity to each other 
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in the ward and they talked about using the NMES unit, different instructions 
for usage may cause confusion or make it obvious which group they were in.   
 
Another limitation noted by this study was that once discharged from hospital 
it became difficult to persuade patients to return for follow up, this would not 
have been such a problem if it was a clinic appointment and patients were 
going to be assessed by medical staff; there seemed to be less incentive to 




The major limitation of this study is the small sample size and the 
heterogeneity of individual results, of the twenty patients recruited (ten in each 
group) only thirteen completed the 4-week trial, and due to this the statistical 
power was not sufficient to reveal the full benefits of NMES. These benefits 
may become apparent after the full trial of forty has been completed. This trial 
could almost be viewed as an investigation into how feasible NMES is in 
practice, or a pilot study preceding the wider study. 
 
 
Further research    
Although research has advocated the use of NMES as an adjuvant therapy in 
pulmonary rehabilitation its efficacy during periods of exacerbation has yet to 
rigorously tested, although some of the results of this study are promising 
there remains much research to be conducted. One such avenue could be the 
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metabolic response at muscle level to NMES during an exacerbation, which 
potentially could prove detrimental by increasing inflammation.  
 
COPD patients exhibit signs of systemic inflammation, elevated levels of 
circulating catecholamines, increased sympathetic activation and muscle 
wasting at rest, it could be expected that physical activity will further increase 
these mediators (Van Helvoort et al 2005). However their study found that 
although exercise did enhance systemic inflammation, it was not exaggerated 
compared to healthy subjects, inflammation just occurred at a higher level and 
at a lower workload. It is worth noting that their sample were free from 
exacerbation for at least two months before commencing the trial.   
Spruit et al (2003) note that during an exacerbation changes in metabolic, 
oxidative, nutritional and inflammatory state occurred, and in addition to 
steroid treatment and bed rest may result in a rapid decrease in muscle force. 
However a study conducted by Sillen et al (2008) found that when compared 
to resistance training NMES produced a significantly lower metabolic 
response; they also iterated that their study did contain some methodological 
limitations, which may limit validity. Spruit et al (2007) elucidate this by 
suggesting that high intensity cycling did increase levels of circulating 
inflammatory markers. Although the sample studied were hospitalised they 
were all clinically stable. 
 
Another measurement that was not taken in this study, which could provide 
additional information, is quadriceps cross-sectional area. Marquis et al 
(2002) suggest that in a cohort of patients that they studied cross-sectional 
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area was a better predictor of mortality than BMI when FEV1 <50%. They 
found that the combination of low predicted FEV1 and cross-sectional area 
<70cm2 led to a rise of 13.16 (CI 95% 1.74 to 99.20) in the mortality odds 
ratio. This could also be used as criteria for targeting the patients most in 
need of rehabilitation or NMES. 
 
Further studies could also look at using different NMES protocols or one leg 
studies to ascertain which is the most beneficial as there are differences 
between those used in previous research. Vivodtzev et al (2008) define high 
frequency NMES as ≥50hz, and that frequencies of 50-120hz lead to 
significant improvements. Different frequencies could be explored. As well as 
different frequencies different duty cycles (on/off times) could be investigated. 
Higher frequencies combined with shorter duty cycles can result in increased 
muscle fatigue, however if larger electrode pads are used patient tolerance 
and quadriceps peak torque can be increased (Lyons et al 2005).     
 
 This study was also restricted by its limited use of activity monitoring. It 
appears that some activity monitors can differentiate between prescribed 
walking and home walking programmes, which can allow for monitoring 
(Hunter et al 2006). In this study activity monitoring was only utilised while 
patients were in hospital in order to compare the baseline physical activity 
levels of the patients in the control and experimental groups. Further research 
could possibly look at patterns of physical activity during hospitalisation and 
following discharge from hospital. Does NMES confine patients to bed? It 
could be that clinicians need to educate patients of the importance of physical 
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activity, and that it is not enough for patients just to use the NMES unit each 
day. 
 
Future research could also look towards tightening the inclusion criteria for 
those recruited for the study. This study recruited patients admitted with an 
acute exacerbation of COPD however in order to target the more disabled 
patients selection could take into account severity of exacerbation and 
baseline levels of exercise tolerance, however this would prove very time 
consuming. It may be that a proportion of less disabled patients may benefit 
more from a voluntary training programme of quadriceps strengthening rather 
than NMES; a direct comparison of the two interventions would be valuable.  
 
 
The current studies decline in strain gauge measurements following discharge 
from hospital may also provide scope for research into compliance with the 
NMES protocol. Levels of compliance could be monitored, some NMES units 
contain software to record how often the device has been worn, qualitative 
research could be conducted to identify barriers to compliance and since 
resources are always scarce this could aid recruitment towards those likely to 
comply. Some patients may also be less likely to participate in physical 
activity as they may feel that since they are using NMES that they do not need 
to, in this case educating the patient is particularly important. A crossover 





In conclusion this study has shown that a 4-week NMES programme is 
feasible for patients suffering an exacerbation of COPD, and may have a role 
in maintaining physical capacity in patients hospitalised with an acute 
exacerbation. However these should be viewed as preliminary findings which 
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Appendix 1  
 
 




0  NOTHING AT ALL 
 
0.5  VERY, VERY SLIGHT 
 
1.0  VERY SLIGHT 
 
2.0  SLIGHT 
 
3.0  MODERATE 
 
4.0  SOMEWHAT SEVERE 
 








9.0  VERY, VERY SEVERE (ALMOST MAXIMAL) 
 







(N.B. There is no ‘right’ or ‘wrong’ way with this scoring.  It is just 
how you feel at the time.  It is helpful for us to know how difficult 
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This scale is used to determine how hard you find the walking.  
There is no right or wrong response.  Please take into account 










Grade   Degree of breathlessness related to activities 
 
1  Not troubled by breathlessness except on strenuous exercise 
 
2 Short of breath when hurrying or walking up a slight hill 
 
3 Walks slower than people of the same age on the level ground 
because of breathlessness or has to stop for breath when 
walking at own pace 
 
4 Stops for breath after walking about 100m or after a few minutes 
on level ground 
 






As appears in the NICE guideline on COPD 
 
Adapted from Fletcher CM, Elmes PC, Fairbairn et al (1959) The significance 
of respiratory symptoms and the diagnosis of chronic bronchitis in a working 





QUESTIONNAIRE (Self Reported) 
This questionnaire 1s designed to f ind out how you have been feeling during the 
last two weeks. You will be asked how short of breath you have been, how tired 
you have been feeling and how your mood has been. 
NAME 
DATE 
University Hospitals of leicester fi!/:k1 
NHS Trust 
(c) 2001 University Hospitals of Le1cester NHS Trust, Glenfield Hospital, UK and McMaster Un1vers1ty, 0Ptario, Canada !All nghts reserved) 
II 
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We would like you to think of ways in which your shortness of breath limits your life. We are 
particularly tnterested in activities which you still do, but which are limited by your shortness 
of breath 
L1sted below are some actiVIties wh1ch can make people with lung problems feel short of 
breath. 
If you have felt short of breath doing any of the activities listed below during the last two 
weeks then please tick each relevant activity. If you have not done the activity dunng the last 
two weeks or 1t does not make you short of breath then leave 1t blank. 
THE ACTIVITIES ARE: 
,1. BEING ANGRY OR UPSET 114. PLAYING SPORTS 
2. HAVING A BATH OR SHOWER 115. REACHING OVER YOUR HEAD 
3. BENDING 16. RUNNING - SUCH AS FOR A BUS 
4. CARRYING - SUCH AS GROCERIES 17. SHOPPING 
5. DRESSING 18. WHILE TRYING TO SLEEP 
6. EATING 19. TALKING 
7. GOING FOR A WALK 20. VACUUMING 
8. DOING YOUR HOUSEWORK 21 . WAlKING AROUND YOUR OWN HOME 
9. HURRYING 22. WALKING UPHILl 
10. MAKING YOUR BED 23. WAlKING UPSTAIRS 
..__....L-1_1._M_o_P_P_IN_G_o_R_s_c_Ru_B_B_IN_G_A_FL_o_o_R __ ___,I I..__....L-2_4._w_A_L_KI_N_G_w_rr_H_o_T_H_ER_s_o_N_LE_v_E_L_GR_o_u_N_D__. 
~~1=2=. M=O=V=IN=G==FU=R=N=IT=U=R=E============~' I..__....L-2_5._P_R_EP_A_R_IN_G_M_E_A_~ _______ ___. 
13. PLAYING WITH CHilDREN/GRANDCHilDREN 
Please hst any other activities that you have done during the last two weeks which have 
made you feel short of breath These should be activities whtch you do frequently and whtch 
are 1mportant in your day-to-day life. 
" 
 110 
We would now like you to identify the most important activities in wh1ch you have been 
limited by your shortness of breath in the last two weeks. 
Usmg the list you have made on the previous page, write down the five most important 
activities that have made you short of breath on the lmes below. We would then like you to 
tell us how short of breath you have been wh ile performing each activity by ticking the box 
which best describes how you feel. 
HOW SHORT OF BREATH HAVE YOU BEEN DURING THE 
LAST TWO WEEKS WHILE PERFORMING THESE ACl"IVITIES7 
Extremely Very Qu,te Modera~e Some 'A little Not at al 
short of short of short of shortness shortness shortness shor of 
breath breath breath of breath of breath of hreath breath 
1. D D D D D D D 
2. D D D D D D D 
3. D D D D D D D 
4. D D D D D D D 
5. 
'10 D D D D D D 
~I 
PLEASE MAKE SURE YOU HAVE COMPLETED THE ABOVE 
TABLE BEFORE TURNING THE PAGE 
T hank you 
El 
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6 . In general, how much of the time during the last 2 weeks 
have you felt frustrated or impatient? 
Please indicate how often during the last 2 weeks you have felt frustrated or impatrent by Licking one of 
the following options from the list below. 
1. ALL OF THE TIME 0 
2. MOST OF THE TIME 0 
3. A GOOD BIT OF THE TIME 0 
4. SOME OF THE TIME 0 
5. A LITTLE OF THE TIME 0 
6. HARDLY ANY OF THE TIME 0 
7. NONE OF THE TIME 0 
7. How often during the past 2 weeks did you have a feeling 
of fear or panic when you had difficulty getting your 
breath? 
Please indicate how often you had a feeling of fear or panic when you had difficulty getting your breath by 
ticking one of the following options from the list below. 
1. ALL OF THE TIME 0 
2. MOST OF THE TIME 0 
3. A GOOD BIT OF THE TIME 0 
4. SOME OF THE TIME 0 
5. A LITTLE OF THE TIME 0 
6. HARDLY ANY OF THE TIME 0 
7. NONE OF THE TIME 0 
8 . What about fatigue 1 How tired have you felt over the last 
2 weeks? 
Please indicate how trred you have felt over the last 2 weeks by tickrng one of the tollowrng options from 
the list below. 
1. EXTREMELY TIRED 0 
2. VERY TIRED 0 
3. QUITE A BIT OF TIREDNESS 0 
4. MODERATELY TIRED 0 
5. SOMEWHAT TIRED 0 
6. A LITTLE TIRED 0 
7. NOT AT ALL TIRED 0 
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9. How often during the last 2 weeks have you felt 
embarrassed by your coughing or heavy breathing? 
Please indicate how much of the time you felt embarrassed by your coughing or heavy breathing by t icking 
one of the following options from the list below. 
1. ALL OF THE TIME 
2. MOST Of THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME 
5. A LITTLE OF THE TIME 
6. HARDLY ANY OF THE TIME 
7. NONE OF THE TIME 
10. In the last 2 weeks, how much of the time did you feel 
very confident and sure that you could deal witll your 
illness? 
Please mdicate how much of the t1me you felt very confident and sure that you could deal with your illness 
by ticking one of the follow1ng options from the list below. 
1. NONE OF THE TIME 8 
2. A LITTLE OF THE TIME 0 
3. SOME OF THE TIME 0 
4. A GOOD BIT OF THE TIME 0 
5. MOST OF THE TIME 0 
6. ALMOST AU OF THE TIME 0 
7. ALL OF THE TIME 0 
11. How much energy have you had in the last 2 weeks? 
Please indicate how much energy you have had by ticking one of the fol lowing options from the list below. 
1. NO ENERGY AT ALL 0 
2. A UTTLE ENERGY 0 
3. SOME ENERGY 0 
4. MODERATELY ENERGETIC 0 
5. QUITE A BIT OF ENERGY 0 
6. VERY ENERGETIC 0 
7. FULL OF ENERGY 0 
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12. 1n general, how much of the time did you feel upset, 
worried or depressed during the past 2 weeks? 
Please indicate how much of the time you felt upset, worried or depressed during the past 2 weeks by 
ticking one of the fol lowing options from the list below. 
1. ALL OF THE TIME 0 
2. MOST OF THE TIME 0 
3. A GOOD BIT OF THE TIME 0 
4. SOME OF THE TIME 0 
5. A UTILE OF THE TIME 0 
6. HARDLY ANY OF THE TIME 0 
7. NONE OF THE TIME 0 
13. How often during the last 2 weeks did you feel you had 
complete control of your breathing problems? 
Please indicate how often you felt you had complete control of your breathing problems by ticking one of 
the following options from the list below. 
1. NONE OF THE TIME 0 
2. A UTILE OF THE TIME 0 
3. SOME OF THE TIME 0 
4. A GOOD BIT OF THE TIME 0 
5. MOST OF THE TIME 0 
6. ALMOST ALL OF THE TIME 0 
1. ALL OF THE TIME 0 
14. How much of the time during the last 2 weeks did you 
feel relaxed and free of tension? 
Please indicate how much of the time you felt relaxed and free of tens1on by ticking one of the following 
options from the list below. 
1. NONE OF THE TIME 0 
2. A UTILE OF THE TIME 0 
3. SOME OF THE TIME 0 
4. A GOOD BIT OF THE TIME 0 
5. MOST OF THE TIME 0 
6. ALMOST All OF THE TIME 0 
7. ALL OF THE TIME 0 
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15. How often during the last 2 weeks have you felt low in 
energy? 
Please indicate how often during the last 2 weeks you have felt low in energy by ticking one of the 
following options from the list below. 
1. All OF THE TIME 
2. MOST OF THE TIME 
3. A GOOD BIT OF THE TIME 
4. SOME OF THE TIME 
5. A UTILE OF THE TIME 
6. HARDLY ANY OF THE TIME 
7. NONE OF THE TIME 
16. In general, how often during the last 2 weeks have you 
felt discouraged or down in the dumps? 
Please indicate how often during the last 2 weeks you felt discouraged or down in the dumps by ticking 
one of the following options from the list below. 
1. ALL OF THE TIME (] 
2. MOST OF THE TIME 0 
3. A GOOD BIT OF THE TIME 0 
4. SOME OF THE TIME 0 
5. A UTILE OF THE TIME 0 
6. HARDLY ANY OF THE TIME 0 
7. NONE OF THE TIME 0 
17. How often during the last 2 weeks have you felt worn 
out or sluggish? 
Please indicate how much of the time you felt worn out or slugg1sh by ticking one of the follow1ng options 
from the list below. 
1. All OF THE TIME 0 
2. MOST OF THE TIME :J 
3. A GOOD BIT OF THE TIME :J 
4. SOME OF THE TIME 0 
5. A UTILE OF THE TIME :r 
6. HARDLY ANY OF THE TIME 0 
7. NONE OF THE TIME 0 
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18. How happy, satisfied or pleased have you been with your 
personal life during the last 2 weeks? 
Please indicate how happy, satrsfred or pleased you have been by t icking one of the following options from 
the list below 
1. VERY DISSATISFIED, UNHAPPY MOST OF THE TIME ::J 
2. GENERALLY DISSATISFIED, UNHAPPY :l 
3. SOMEWHAT DISSATISFIED, UNHAPPY ::J 
4 . GENERALLY SATISFIED, PLEASED ::J 
5. HAPPY MOST OF THE TIME 0 
6. VERY HAPPY MOST OF THE TIME u 
7. EXTREMElY HAPPY, COUlD NOT HAVE BEEN 
MORE SATISFIED OR PlEASED 0 
19. How often during the last 2 weeks did you feel upset or 
scared when you had difficulty getting your breath? 
Please rndrcate how often dunng the past 2 weeks you telt upset or scared when you had difficulty getting 
your breath by tickrng one of the follow1ng options from the list below 
1. All OF THE TIME 0 
2. MOST OF THE TIME 0 
3. A GOOD BIT OF THE TIME 0 
4. SOME OF THE TIME 0 
5. A UTilE OF THE TIME 0 
6. HARDLY ANY OF THE TIME 0 
7. NONE OF THE TIME l_j 
20. In general how often during the last 2 weeks have you 
felt restless, tense or uptight? 
Please rndicate how often you have felt restless. tense or uptight by trckrng one of the followrng optrons 
from the list below. 
1. All OF THE TIME a 
2. MOST OF THE TIME a 
3. A GOOD BIT OF THE TIME a 
4. SOME OF THE TIME a 
5. A UTILE OF THE TIME 0 
6. HARDLY ANY OF THE TIME 0 
7. NONE OF THE TIME 0 




Your nurse is aware that emotions play an important part in your illness and treatment.  If your nurse 
knows about these feelings he will be able to help you more. 
 
This questionnaire is designed to help your nurse to know how you feel.  Read each item and place a 
firm tick in the box opposite the reply, which comes closest to how you have been feeling in the past 
week. 
 
Don’t take too long over your replies; your immediate reaction to each item will probably be more 
accurate than a long thought-out response. 
 
Tick one box only in each section 
1 I feel tense or wound up: 
Most of the time 
A lot of the time 
Time to time, occasionally 
Not at all 
 
2  I still enjoy the things I used to enjoy: 
Definitely as much 
Not quite so much 
Only a little  
Hardly at all           
 
3  I get a sort of frightened feeling as if 
something awful is about to happen: 
Very definitely and quite badly 
Yes, but not too badly 
A little, but it doesn’t worry me 
Not at all   
 
4  I can laugh and see the funny side of 
things: 
As much as I always could 
Not quite so much now 
Definitely not so much now 
Not at all             
 
5  Worrying thoughts go through my mind: 
A great deal of the time               
A lot of the time 
From time to time bur not too often 
Only occasionally 
 
6  I feel cheerful 
Not at all 
Not often 
Sometimes 
Most of the time 
 
 



















































8  I feel as if I am slowed down: 
Nearly all the time 
Very often 
Sometimes 
Not at all 
 
9  I get a sort of frightened feeling like 
“butterflies” in the stomach: 
Not at all 
Occasionally 
Quite often 
Very often  
 
10  I have lost interest in my appearance: 
Definitely 
I don’t take so much care as I should 
I may not take quite as much care  
I take just as much care as ever 
 
11 I feel restless as if I have to be on the 
move: 
Very much indeed 
Quite a lot 
Not very much 
Not at all 
 
12 I look forward with enjoyment to things: 
As much as I ever did 
Rather less than I used to  
Definitely less than I used to  
Hardly at all 
 
13 I get sudden feelings of panic: 
Very often indeed 
Quite often 
Not very often 
Not at all 
 

















































































How To Put The Activity Monitor Device On Yourself 
What Does The Activity Monitor 
Device Measure? 
The Activity Monitor Device has sensors 
that detect movement.  
From this data the Activity Monitor 
Device calculates energy expenditure as 
well as amount of time active, lying 
down and sleeping.    
 
How To Put The Activity Monitor Device On Yourself 
The Activity Monitor Device is to be worn on the back above the elbow of your right arm. 
Position Activity Monitor with the timestamp button above the battery cover and slide the 
device along the back of the arm mid way between the elbow and the shoulder. Adjust the strap 
so that it fits onto your arm comfortable and secure with the Velcro. Please take care not to 
adjust the strap too tightly, if your arm begins to tingle, lose feeling or is uncomfortable loosen 
the strap. 
Once you have put the monitor on the device will switch itself on and will give off a tone (do-
de-do-deet) and then will vibrate for two seconds. 
To take off the arm simply loosen the strap and slide down the arm and take off the device once 
off will give off a tone (de-de-deet).  
When To Wear It And When To Take It Off 
You can wear the monitor while you are up and about as well as while you are lying or 
sleeping. However you should always remove while you are washing so not to get the device 
wet. You must also remove while you are using the Muscle Stimulators so there is no electrical 
interference. If there is any skin irritation caused by wearing the device please remove it, only 
replace you are comfortable to put the monitor back on. 
 
How Long Can It Be Used For? 
The battery life of the Activity 
Monitor Device is on average 14 days 
and the memory capacity for the 
device is 10 days and 21 hours. The 
data can be transferred on to 
computer before filled and the 
batteries can be easily replaced. 
 








1. Sit down in a comfortable position with your legs supported and stretched 
out in front of you. 
 
2. Then expose the top part of you leg to reveal the Quadriceps muscle (this 
is the muscle that runs on the front of your thigh between your hip and your 
knee). 
 
3. Gently un-peal your stickers from their plastic backing one at a time and 
place on the legs as the picture below shows: (2 just above the knee at an 

















4. Then attach the leads from the device to the leads attached to the sticky 
pads. The red connector goes into the pad at the top of the leg and the black 









5. Turn the device on by pressing the red button. The programme you are on 




6. Gradually turn up the device on both sides by pressing the up buttons (see 
below). Keep turning the device up until you start to feel the tingling and 





7. The device automatically counts 20 minutes for you so when it has finished 
turn the device off using the red button again and unplug the connectors from 
the sticky pads. 
 
8. Gently peel the sticky pads off your legs and place back onto the protective 














1. Sit down in a comfortable position with your legs supported and stretched 
out in front of you. 
 
2. Then expose the top part of you leg to reveal the Quadriceps muscle (this 
is the muscle that runs on the front of your thigh between your hip and your 
knee). 
 
3. Gently un-peel your stickers from their plastic backing one at a time and 
place on the legs as the picture below shows: (2 just above the knee at an 

















4. Then attach the leads from the device to the leads attached to the sticky 
pads. The red connector goes into the pad at the top of the leg and the black 









5. Turn the device on by pressing the red button. The programme you are on 




6. Gradually turn up the device on both sides by pressing the up buttons (see 
below). Keep turning the device up until you start to feel the sensation or 






7. The device automatically counts 20 minutes for you so when it has finished 
unplug the connectors from the sticky pads. 
 
8. Gently peel the sticky pads off your legs and place back onto the protective 






















  Appendix 7. 
Chronic Respiratory 
Questionnaire 
(Self Reported) - Follow up 
Name: 
Date: 
You have previously completed a questionnaire telling us about how you have 
been feeling and how your lung disease has affected your life. This is a follow-
up questionnairedesigned to find out how you have been getting on since 
then. 
c 2001. University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester UK LE3 9QP 
McMaster University, Ontario, Canada (all rights reserved) 
c 2001. University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester UK LE3 9QP 
McMaster University, Ontario, Canada (all rights reserved) 
 
c 2001. University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester UK LE3 9QP 
McMaster University, Ontario, Canada (all rights reserved) 
 
 
Chronic Respiratory Questionnaire 
We asked you previously to identify the five most important activities in 
your life which were limited by shortness of breath. Listed below is the 
list of activities which you selected. Please could you tell us how short of 
breath you have been in the last two weeks while performing each activity 
by ticking the box which best describes how you feel. 
How short of breath have you been during the last two weeks 
while performing these activities? 
Extremely Short of Breath 
Very Short of Breath 
Quite Short of Breath 
Moderate Shortness of Breath 
Some Shortness of Breath 
A little Shortness of Breath 







Please make sure you have completed the above 
table before continuing onto the multiple choice 
questions on the next page................ 
The activities are: Please one box per activity 
c 2001. University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester UK LE3 9QP 
McMaster University, Ontario, Canada (all rights reserved) 
 
Chronic Respiratory Questionnaire 
6. In general, how much of the time during the last 2 weeks have you felt 
frustrated or impatient? 
Please indicate how often during the last 2 weeks you have felt frustrated 
or impatient by ticking one of the following options from the list below. 
1 All of the time _ 
2 Most of the time _ 
3 A good bit of the time _ 
4 Some of the time _ 
5 A little of the time _ 
6 Hardly any of the time _ 
7 None of the time _ 
7. How often during the past 2 weeks did you have a feeling of fear or panic 
when you had difficulty getting your breath? 
Please indicate how often you had a feeling of fear or panic when you had difficulty 
getting your breath by ticking one of the following options from the list below. 
1 All of the time _ 
2 Most of the time _ 
3 A good bit of the time _ 
4 Some of the time _ 
5 A little of the time _ 
6 Hardly any of the time _ 
7 None of the time _ 
8. What about fatigue? How tired have you felt over the last 2 weeks? 
Please indicate how tired you have felt over the last 2 weeks by ticking one 
of the following options from the list below. 
1 Extremely tired _ 
2 Very tired _ 
3 Quite a bit of tiredness _ 
4 Moderately tired _ 
5 Somewhat tired _ 
6 A little tired _ 
7 Not at all tired _ 
c 2001. University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester UK LE3 9QP 
McMaster University, Ontario, Canada (all rights reserved) 
 
9. How often during the last 2 weeks have you felt embarrassed by your 
coughing or heavy breathing? 
Please indicate how much of the time you felt embarrassed by your coughing or heavy 
breathing by ticking one of the following options from the list below. 
1 All of the time _ 
2 Most of the time _ 
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3 A good bit of the time _ 
4 Some of the time _ 
5 A little of the time _ 
6 Hardly any of the time _ 
7 None of the time _ 
10. In the last 2 weeks, how much of the time did you feel very confident and 
sure that you could deal with your illness? 
Please indicate how much of the time you felt very confident and sure that you could 
deal with your illness by ticking one of the following options from the list below. 
1 None of the time _ 
2 A little of the time _ 
3 Some of the time _ 
4 A good bit of the time _ 
5 Most of the time _ 
6 Almost all of the time _ 
7 All of the time _ 
11. How much energy have you had in the last 2 weeks? 
Please indicate how much energy you have had by ticking one of the following options 
from the list below. 
1 No energy at all _ 
2 A little energy _ 
3 Some energy _ 
4 Moderately energetic _ 
5 Quite a bit of energy _ 
6 Very energetic _ 
7 Full of energy _ 
c 2001. University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester UK LE3 9QP 
McMaster University, Ontario, Canada (all rights reserved) 
 
12. In general, how much of the time did you feel upset, 
worried or depressed during the past 2 weeks? 
Please indicate how much of the time you felt upset, worried or depressed 
during the past 2 weeks by ticking one of the following options from the list below. 
1 All of the time _ 
2 Most of the time _ 
3 A good bit of the time _ 
4 Some of the time _ 
5 A little of the time _ 
6 Hardly any of the time _ 
7 None of the time _ 
13. How often during the last 2 weeks did you feel you had 
complete control of your breathing problems? 
Please indicate how often you felt you had complete control of your breathing 
problems by ticking one the following options from the list below. 
1 None of the time _ 
2 A little of the time _ 
3 Some of the time _ 
4 A good bit of the time _ 
5 Most of the time _ 
6 Almost all of the time _ 
7 All of the time _ 
14. How much of the time during the last 2 weeks did you 
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feel relaxed and free of tension? 
Please indicate how much of the time you felt relaxed and free of 
tension by ticking one of the following options from the list below. 
1 None of the time _ 
2 A little of the time _ 
3 Some of the time _ 
4 A good bit of the time _ 
5 Most of the time _ 
6 Almost all of the time _ 
7 All of the time _ 
c 2001. University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester UK LE3 9QP 
McMaster University, Ontario, Canada (all rights reserved) 
 
15. How often during the last 2 weeks have you felt low in energy? 
Please indicate how often during the last 2 weeks you have felt low in energy by 
ticking one of the following options from the list below. 
1 All of the time _ 
2 Most of the time _ 
3 A good bit of the time _ 
4 Some of the time _ 
5 A little of the time _ 
6 Hardly any of the time _ 
7 None of the time _ 
16. In general, how often during the last 2 weeks have you 
felt discouraged or down in the dumps? 
Please indicate how often during the last 2 weeks you felt discouraged or down in the 
dumps by ticking one of the following options from the list below. 
1 All of the time _ 
2 Most of the time _ 
3 A good bit of the time _ 
4 Some of the time _ 
5 A little of the time _ 
6 Hardly any of the time _ 
7 None of the time _ 
17. How often during the last 2 weeks have you felt worn out or sluggish? 
Please indicate how much of the time you felt worn out or sluggish by ticking one of 
the following options from the list below. 
1 All of the time _ 
2 Most of the time _ 
3 A good bit of the time _ 
4 Some of the time _ 
5 A little of the time _ 
6 Hardly any of the time _ 
7 None of the time _ 
c 2001. University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester UK LE3 9QP 
McMaster University, Ontario, Canada (all rights reserved) 
 
18. How happy, satisfied or pleased have you been with your 
personal life during the last 2 weeks? 
Please indicate how happy, satisfied or pleased you have been by ticking one 
of the following options from the list below. 
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1 Very dissatisfied, unhappy most of the time _ 
2 Generally dissatisfied, unhappy _ 
3 Somewhat dissatisfied, unhappy _ 
4 Generally satisfied, pleased _ 
5 Happy most of the time _ 
6 Very happy most of the time _ 
7 Extremely happy, could not have been 
more satisfied or pleased _ 
19. How often during the last 2 weeks did you feel upset or scared 
when you had difficulty getting your breath? 
Please indicate how often during the last 2 weeks you felt upset or scared when you had 
difficulty getting your breath by ticking one of the following options from the list below. 
1 All of the time _ 
2 Most of the time _ 
3 A good bit of the time _ 
4 Some of the time _ 
5 A little of the time _ 
6 Hardly any of the time _ 
7 None of the time _ 
20. In general, how often during the last 2 weeks have you 
felt restless, tense or uptight? 
Please indicate how often you have felt restless, tense or uptight by ticking one of 
the following options from the list below. 
1 All of the time _ 
2 Most of the time _ 
3 A good bit of the time _ 
4 Some of the time _ 
5 A little of the time _ 
6 Hardly any of the time _ 
7 None of the time _ 





CONSENT FORM (Version 3, 19/06/07) 
 
Identification Number for this study: 07/Q2501/5 
 
Is neuromuscular electrical stimulation effective in maintaining 
physical capacity during an exacerbation of COPD? 
    
          Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 
19/06/07 version 3 for the above study and have had the opportunity to 
ask questions.         
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at 
by responsible individuals or from regulatory authorities where it is 
relevant to my taking part in research.  I give permission for these 
individuals to have access to my records. 
 
4. I agree to take part in the above study. 
 
5. I agree for my consultant to be informed of my participation. 
 
  
   
 
 
______________________  _________ ____________ 




______________________  _________ ____________ 
Name of Person taking consent  Date Signature 
(if different from researcher) 
 
 
______________________  _________ ____________ 
Researcher    Date  Signature 
1 for patient;  1 for researcher;  1 to be kept with hospital notes 
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Dear Dr  
 
Study title: Neuromuscular electrical stimulation is effective in 
maintaining physical capacity during an exacerbation of COPD.  
 
A study has been designed to establish whether neuromuscular electrical 
stimulation is an effective adjuvant rehabilitative therapy, suitable during an 
exacerbation of COPD. 
On Admission to hospital patients quadriceps strength, and incremental 
shuttle walk distances will be tested. They will be asked to wear activity 
monitors. The treatment group will receive quadriceps muscle stimulation for 
30 minutes each day on each leg for a total of 6 weeks, patients will be asked 
to administer this on discharge from hospital. The control group will receive 
stimulation at sub-therepeutic levels. 6 weeks after commencing the 
stimulation patients will be recalled and their quads strength and shuttle walk 
distances will once again be tested.   
 
We would be grateful if we could obtain your permission to approach the 
patients under your care.  
 
If you require any further information please do not hesitate to contact me on 








Sally Singh PhD 







PATIENT INFORMATION SHEET  
(Version  3  19/06/07) 
 
1. Study title:  
Neuromuscular electrical stimulation is effective in maintaining 
physical capacity during an exacerbation of COPD.  
 
 
You are being invited to take part in a research study being conducted by the pulmonary 
rehabilitation team in conjunction with Coventry University. Before you decide it is important 
for you to understand why the research is being done and what it will involve.  Please take 
time to read the following information carefully and discuss it with others if you wish.  Ask us 
if there is anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part.  Thank you for reading this. 
 
2. What is the purpose of the study? 
There is evidence to suggest that muscle stimulation is a beneficial component of 
rehabilitation for sufferers of Chronic Obstructive Pulmonary Disease (COPD). However this 
has only been investigated in patients whose disease is stable.  We also know that during 
hospitalisation there is a decline in the overall function of your leg muscles.  We hope to 
prevent this decline by applying a device that will stimulate your muscle. 
 
3.  Why have I been chosen? 
You have been identified as suitable to participate in this study because you have been 
admitted to hospital with a worsening of your COPD.  
 
4. Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason.   
 
5. What will happen to me if I take part? 
Once you have agreed to take part in the research you will be visited by a member of the 
research team. You will have an opportunity to ask any questions you may have, and you 
will be asked to sign a consent form to confirm your participation. With your permission we 
will also contact your consultant to check that they are agreeable to your participation. 
Sometimes we don’t know which way of treating patients is best. To find out we need to 
make comparisons between the different treatments. We put people into groups and give 
each group a different treatment; the result are compared to see if one is better. To try to 
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make sure the groups are the same to start with, each participant is put into a group by 
chance (randomly). The results are then compared. There is a one in two chance of getting 
the treatment. The trial is also ‘blind’. In a ‘blind trial’ you will not know which treatment 
group you are in.  
 
 
6. What do I have to do? 
The research will consist firstly of a measure of the strength of your thigh muscle, this is 
entirely painless, we will also ask that you complete a simple exercise test, and wear an 
activity monitor. You will then be randomised to receive either the active or placebo 
treatment. You will than be introduced to the muscle stimulation unit, we would ask that you 
place the pads on each thigh for thirty minutes a day for the four  week duration of the study, 
you will be taught how to use the unit prior to your discharge from hospital. This treatment 
would continue at home regardless of the group you were allocated to.  The device is very 
similar to a ‘slendertone’ type of  equipment. Athletes often use the Equipment when they are 
injured to restore muscle function. The device produces a tingling sensation, which is not 
uncomfortable When you are ready to be discharged we will repeat the muscle strength test, 
and the exercise test. Four weeks after beginning the study you will be invited to return to the 
Glenfield Hospital to repeat the tests and again after 6 months. Travel expenses will be paid. 
At the beginning and end of the study you will also be requested to complete a simple 
questionnaire regarding your current state of health.  
 
 
7. What are the possible disadvantages and risks of taking part? 
There are no foreseeable side effects of taking part, however completing the muscle 
stimulation for the Four -week period may cause some inconvenience. 
 
8. What are the possible benefits of taking part? 
We hope that the research will inform further rehabilitative strategies for patients with COPD 
who suffer an exacerbation, and possibly prevent future readmission to hospital.   
 
10. What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangement. If you are harmed due to someone’s negligence, then you may have grounds 
for a legal action but you may have to pay for it. Regardless of this, if you wish to complain, 
or have any concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints mechanisms 
would be available to you. Advice can also be sought from the Patient Advice and Liaison 




11. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. Participants will not 
be identified in any subsequent written material, for example, pseudonyms will be used to 
refer to participants’ names.  Any information that you give will be used for research 
purposes only. Results will be reported in such a way that completely preserves 
confidentiality.  
 
12. What will happen to the results of the research study? 
The results of the study will be disseminated in a thesis towards a masters degree, results 
may also be reported in professional publications and presentations made at relevant 
conferences. Results will be reported in such a way that preserves confidentiality. All 
participants will be given an opportunity to receive a summary of the results if interested. 
You will not be automatically sent one in order to keep financial costs to a minimum, but will 
be given an opportunity to request one at your 4 week follow up.  
 
13. Who is organising and funding the research? 
This study is being funded by the Pulmonary Rehabilitation Research Group and the 
Pulmonary and Rehabilitation team will be organising the study and recruiting participants. 
   
14. Who has reviewed the study? 
All research that involves NHS patients or staff, information fro NHS medical records or 
uses NHS premises or facilities must be approved by an NHS research Ethics Committee 
before it goes ahead. Approval does not guarantee that you will not come to any harm if you 
take part. However, approval means that the committee is satisfied that your rights will be 
respected, that any risks have been reduced to a minimum and balanced against possible 
benefits and that you have been given sufficient information of which to make an informed 
decision.  
 
15. Contact for further information  
If you have any concerns or other questions about this study or the way it has been carried 
out, you should contact the principal researcher (Sally Singh Tel:0116 2502535)  
 
 
Contact for further information: 
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Sally Singh, head of cardiac and pulmonary rehabilitation 
Glenfield Hospital 
Groby Road  
Leicester 
LE3 9QP 
 email s.singh@uhl-tr.nhs.uk 
 
 



















                                          Appendix 11 
                         Ethical approval
 
This form has been removed for copyright reasons 
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